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DEAR READER
This Supplement to the BIOMEDICAL PAPERS, 
Volume 150 (Biomed Pap Med Fac Univ Palacky Olo-
mouc Czech Repub), is devoted to the 33rd Congress of 
the Czech Society of Pathologists and the 2nd Satelite 
Symposium & Workshop on Molecular Pathology held 
at the Regional Centre Olomouc & Faculty of Medicine, 
Palacký University Olomouc, May 4–6, 2006.
The BIOMEDCIAL PAPERS (formerly ACTA UNI-
VERSITATIS PALACKIANAE OLOMOUCENSIS 
 FACULTATIS MEDICAE, Volumes 1–144, Volume 1, 
first published in 1955) is a peer-reviewed international 
journal. Main features of this journal include: 
• Frequency: 1 volume, 2 issues per year
• ISSN: 1213-8118
• Online version: http://biomed.papers.upol.cz
• Indexed in: MEDLINE, CHEMICAL ABSTRACTS, 
BIBLIOGRAPHIA MEDICA CECHOSLOVACA
• Free full text articles available via PubMed Linkout 
Service from Vol. 146 (2002).
• Scope:
 The journal is internationally oriented. Its main prior-
ity is to publish key reviews from all biomedical fields 
with the emphasis on clinical-pathological correla-
tions, and clinical and laboratory diagnostics. Thus, 
this Journal plays an important role in postgraduate 
medical education and also represents a valued pub-
lication forum for postgraduate students. Original 
papers on fundamental clinical and laboratory medi-
cal research as well as on physiological, epidemiologi-
cal and toxicologial studies are also accepted. Brief 
communications describing simple modifications of 
laboratory methods and clinical case reports are also 
welcome. 
• Peer-review process
 Manuscripts are evaluated by the editorial board and 
by a panel of independent reviewers. The process lasts 
up to 4 weeks. The time period from the acceptance 
of a manuscript to its publication does not exceed 
4 months. 
I hope that the content of this Supplement will not 
only represent a basic brochure useful to all participants 
of the Conference but also provide a lot of valuable new 
information on recent results of leading laboratories work-
ing in all the fields of pathology. 
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THE 100TH ANNIVERSARY OF THE HOSPITAL DEPARTMENT OF PATHOLOGY 
AND THE 60TH ANNIVERSARY OF THE INSTITUTE OF PATHOLOGY OF THE MEDICAL 
FACULTY, PALACKÝ UNIVERSITY IN OLOMOUC
Rostislav Koďousek
Institute of Pathology & Laboratory of Molecular Pathology, Faculty of Medicine, Palacký University, Hněvotínská 3, 
775 15 Olomouc, Czech Republic
At this time, several important anniversaries are com-
memorated in relation to the Institute of Pathology of 
the Medical Faculty and the Department of Pathology of 
the Faculty Hospital in Olomouc. Firstly, it is 110 years 
since the completion of a New District Hospital in Nová 
Ulice in Olomouc in 1896. Second, it is 100 years since 
the foundation of the Pathology Department and finally, 
it is the 60th anniversary of the Institute of Pathology of 
the Medical Faculty following the restitution of Palacký 
University in Olomouc on 21st February 1946.
The above-mentioned 100th anniversary of the Patho-
logy Department is of special importance for the current 
institute. From the outset, the department undertook not 
only autopsy and diagnostic-histological work but also a 
wide range of other activities, particularly bacterio logy, 
clinical chemistry, experimental work (animal tests mainly 
for infectology purposes), as well as scientific work in-
cluding cooper0ation with clinicians. During its long ex-
istence, the department was influenced by the work of 
generations of its leader and hundreds of employees of 
various levels and specialization. Gradually, their efforts 
led to the modern Institute of Pathology with the high 
standard of activities, research and teaching, an important 
part of the present-day Palacký University Medical Faculty 
and Faculty Hospital in Olomouc.
The University Institute of Pathology founded 60 years 
ago as part of the re-established University in Olomouc 
continued its more than 200-year-old tradition of teaching 
anatomy and later pathology at the old Olomouc Univer-
sity based at the Philosophical Faculty since 1778 and 
historical health care facilities – the State Hospital created 
by fusion of the old church hospitals (Hospitales Sanctu 
Spiriti) in 1785 and the School of Medicine and Surgery 
(1787–1875). Prominent anatomists and pathologists of 
that time include the state hospital prosector G. Wezel 
(1786–1788), J. John (1807–1853; a founder of the ana-
tomical cabinet – “Theatrum anatomicum”), R. Heschel 
(1854–1855; an assistant to professor K. Rokitanský at 
University of Vienna; author of a pathology manual called 
“Compendium Pathologico-Anatomicum”) and Arthur 
Willigk (1855–1881), originally an assistant-pathologist 
in Prague (1850–1855), later a professor of the School of 
Medicine and Surgery (1869) and a founder of an exten-
sive collection of pathological-anatomical preparations 
“Museum pathologicum”.
For a long time, the School of Medicine and Surgery 
(1787–1875) was a parallel part of the university-type 
Lyceum with leading personalities such as Professor A. 
Willigk, Andreas Jeitteles-Justus Frey – collections of 
pathological-anatomical preparations, Filip Hartman 
(1806–1811) – a manual of pathology used at that time 
in the Austro-Hungarian Monarchy, and J. Mošner – a 
manual of obstetrics.
It was at the University of Olomouc that the founder 
of classical genetics J. G. Mendel began his studies. (His 
work on experimental genetics was published in 1865 in 
the Brno Natural Science Society Journal).
The University in Olomouc is among the oldest in Cen-
tral Europe and the second oldest, after Prague’s Charles 
University in our country. Originally founded as a Jesuit 
Rostislav KOĎOUSEK, prof., MUDr., DrSc.
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college by Bishop Vilém Prusinovský between 1566 and 
1573, it was turned into a university with a papal seminary 
Collegium Nordicum in 1573. The foundation charter of 
Pope Gregory XIII and Emperor Maximilian II (“Great 
confirmation privilege”) gave the university the right to 
confer degrees and the same position and rights as those 
of other European universities in Germany, France, Italy 
and Spain. The following stages of its history were char-
acterized by periods of both prosperity and decline, inter-
rupted teaching caused by the plague epidemic until 1715, 
and repeated abolition – the anti-Habsburg uprising of 
the Czech estates and the Jesuit exodus from Olomouc 
(1618–1620), the Thirty Year’s War (1618-1648) and the 
7-year Swedish military occupation of Olomouc. In 1782 
the institution was reopened but only as a lower 3-year 
”Lyceum”. Soon after 1848 the School of Medicine and 
Surgery was established (named “K. und K. Medizin-
Chirurgische Anstalt”).
In 1827, the Austrian Emperor, Francis I promoted 
the “Lyceum” to a university (“Caesaro-Regia Universi-
tas Franciscea Olomucensis”). However, after the 1848-
1849 revolution was suppressed, the emperor’s court was 
moved from Vienna to the Olomouc fort and the period 
of Bach’s absolutism began. The university was abolished 
once again in 1860 and its rector’s historical insignia were 
first transferred to Brno and later to the University in 
Innsbruck, Austria. Only the theological faculty remained 
in Olomouc until 1939 when all Czech high schools were 
closed during the German military occupation.
The health care facilities also underwent very compli-
cated developments. Between 1785 and 1787, municipal 
hospitals were joined into one state-administered hospital 
with departments of surgery, internal medicine and ob-
stetrics, and an orphanage. Since 1862, the hospital was 
administered by the country of Moravia as the Moravian 
General Country Institutes in Olomouc with a capacity 
of 184 beds and 20 children’s beds. The hospital was lo-
cated in the place of the present-day university buildings 
in Křížkovský street.
The new boom of the hospital facility dates back to 
1892 (after the town fortifications were torn down in 
1886) when the Moravian assembly decided to build a 
new hospital (1892–1896) in the new Olomouc area of 
Nová Ulice – Tabulový vrch. The New Moravian General 
Country Institutes were the basis of the later Faculty Hos-
pital. Ten years later, in 1906, the pathology department 
was established, first headed by Dr F. Berka (1906–1920), 
later a professor at the Institute of Forensic Medicine of 
Masaryk University in Brno. Shortly after, between 1920 
and 1922, the department was led by Dr V. Neumann, later 
a professor and the head at the Institute of Pathology of 
Masaryk University in Brno, and then by Professor Dr 
J. Kabelík (1922–1939). During World War II the head 
was Dr J. Jung.
After the university was renewed in 1946 and named 
“Palacký University” – according to a well-known Czech 
historian, politician and cultural worker František  Palacký 
(1798–1876) – the Medical Faculty was founded. The 
Institute of Pathology was headed by Professor Dr. F. 
Pavlica (until 1948), Doc. Dr K. Kučera and Prim. Dr 
Krajčiřík (1948-1949), Doc. Dr Č. Dvořáček (1949–1958) 
– the establishment of the Catheder of Pathology of the 
Medical Faculty of Palacký University. In 1958–1960 the 
acting head was Dr R. Koďousek.
In 1960 the Institute of Pathology was moved to a new 
medical faculty building (the “Theoretical Institutes”) and 
headed by Doc. Dr V. Valach (1960–1974). In 1964 the 
Research Laboratory of Cyto- and Histochemistry was es-
tablished (headed by Doc. Dr R. Koďousek, 1964–1974), 
closely cooperating with the Czechoslovak Society of 
Cyto- and Histochemistry, a part of the Czechoslovak 
Academy of Sciences.
Between 1974 and 1994, when the institute was led 
by Professor Dr R. Koďousek, it was organized into spe-
cialized divisions including an integrated biopsy service 
(according to a Swedish model). Simultaneously, efforts 
to introduce systemic classification and computerization 
of biopsy findings were initiated (Dr P. Vácha). The Sec-
tion of Clinical Pathology and Cytology was established in 
1976 as part of the Society of Czechoslovak Pathologists. 
Diagnostic and scientific research activities of the institute 
were supported by the division of electron microscopy 
(Professor Dr J. Dušek), cytology diagnostics, hepatopa-
thology (Dr V. Jezdinská), neuropathology (Dr Z. Ska-
tula, Dr O. Rozhold), dermatopathology (Dr O. Černý) 
and perinatal pathology (Dr L. Židová). The health care 
service section of the department was led by Prim. Dr K. 
Vojáček. The stomatopathological section for dentistry 
students was directed by Prof. Dr P. Jansa.
After return from a stay at McGill University in Can-
ada, Professor Dr J. Dušek was the head of the Institute 
of Pathology for the period 1994–2000. He was also a 
prominent Palacký University representative (a vice-rector 
for scientific and research work) and education innovator 
(introduction of the “PBL” system – problem-based learn-
ing – and pathology lessons taught in English to foreign 
medical students).
Following Professor J. Dušek’s tragic death in 2000, 
the institute has been directed by Professor Dr Z. Kolář, 
an organizer of the modernization and reconstruction of 
the laboratories, scientific researcher and founder of the 
Research Laboratory of Molecular Pathology.
After Professor Z. Kolář became the Dean of the Med-
ical Faculty of the Palacký University in 2004, the leading 
post in the institute has been held by Doc. Dr M. Tichý 
who continues to safeguard the progressive trends of the 
Institute, both in the health care divisions as well as in the 
education of medical students. He is also a co-organizer 
of this national congress.
Of former personalities we should especially acknowl-
edge the work of Doc. Dr Č. Dvořáček (1949–1958), a 
founder of the university-type institute of pathology, or-
ganizer of a network of many pathology institutes in the 
North Moravia region and representative of the so called 
school of North-Moravian pathologists. During Doc. Dr 
V. Valach’s era the diagnostic health care service reached 
its heights with more than 20 thousand biopsies and 
nearly 2,500 autopsies a year. This state remained until 
9pathology institutes all over North Moravia were taken 
over by experienced pathologists, mainly trained at the 
Institute of Pathology in Olomouc.
Many outstanding professionals and several Palacký 
University dignitaries began their careers at the Institute 
of Pathology, including 13 leading pathologists in regional 
pathological departments, 6 heads of university institutes 
and several specialists working abroad (Great Britain, 
USA, Canada).
We would also like to briefly mention the current situ-
ation at the institute. It comprises several divisions. The 
diagnostic health care services (Prim Dr L. Kučerová) 
include autopsies, routine and peroperative biopsies and 
cytology diagnostics and a special reference laboratory for 
oncological diagnostics (special orientation to breast can-
cer). Important scientific and research activities are also 
seen in the recently established research laboratory for 
molecular pathology. We should also mention other areas 
such as neuropathology (earlier work on prion diseases), 
nephropathology, hepatopathology (liver biopsies), on-
cohematology, malignant lymphomas and immunohisto-
chemistry.
The teaching programmes for medical students include 
the study of pathology along general medicine, dentistry 
and bachelor science degree lines. A programme in Eng-
lish for foreign students is also in existenced. The insti-
tute has also been accredited for postgraduate doctoral 
studies.
The scientific and research activities have traditionally 
been of high a methodological level in all divisions. In the 
past, these were supported by the Research laboratory of 
cyto- and histochemistry (Professor Dr R. Koďousek), 
electron microscopy laboratory (Professor Dr J. Dušek), 
and later – especially in routine diagnostic work – by the 
immunohistological laboratory (Professor Dr J. Mačák). 
At present, in addition to histochemistry, methods of 
molecular pathology and genetics are used in the Re-
search laboratory of molecular pathology (Professor Dr 
Z. Kolář) in cooperation with some research institutions 
of the university.
For its scientific, research and publishing activities, the 
Institute has gradually become one of the well-recognized 
university centres in our country. The institute members 
have published a number of original papers in the field 
of applied clinical-pathological research which have re-
ceived favourable international response. An example in-
cludes research on the introduction of macro-enzymatic 
histochemistry in necroptic pathology of ischemic condi-
tions (succino-/malico-dehydrogenase macroreactions in 
acute encephalomalatias, early heart lesions in coronary 
insufficiency and early phases of myocardial infarction). 
Other research has focused on the etio-pathogenesis of 
Whipple’s disease including demonstration of bacterial 
agent in enterobiopsies and in cases of Whipple’s en-
cephalopathy. Publication of original research on human 
pulmonary Adiaspiromycosis defining a new nosological 
entity in medicine attracted unusual attention. Another 
important research was that concerning experimentally in-
duced demyelinization of the brain and spinal cord using 
copper-binding metal chelating agents (Dr J. Můr and Dr 
M. Záruba). From more recent communications, an origi-
nal observation proving positivity of aspartate-protease 
Cathepsin D in the case of cytoinvasive stages of Coc-
cidia (possible spreading factor in coccidiosis) is worth 
mentioning. Extensive materials were gathered in coop-
eration with other institutions including those abroad, 
which enabled publication of a monograph on medically 
significant mycotic diseases. A wide range of papers on 
molecular pathobiology have also been published in a 
number of international journals. These include special 
issues of immunohistochemical diagnostics, interpretation 
and prognostic factor evaluation.
The qualifications of the institute personnel include 
2 doctor of sciences dissertations, 4 professors of patho-
logy, 6 assistant professors and several PhD academic 
titles.
The effort to maintain the high qualification level 
can be demonstrated by the acquired accreditation for 
postgraduate doctoral studies and scientific doctoral dis-
sertations.
Looking back at the time since the pathology depart-
ment of the hospital in Olomouc and the medical faculty 
institute of pathology were established, we can see the 
progressive trend in development towards the present-
day modern institute with excellent facilities located in 
the building of the Theoretical Institutes of the Medical 
Faculty. The institute of pathology has become a signifi-
cant part of the Medical Faculty of Palacký University 
integrating at the present time seven faculties with more 
than 18,000 students.
In the previous years, the Institute of Pathology was 
developed thanks to many staff members, heads, scientific 
and research workers and teachers who deserve appre-
ciation for their work. This is an opportunity to remind 
ourselves of a classic quotation characterizing an individu-
al’s contribution to common efforts: “Suum cuique decus 
rependit posteritas”.
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PREDICTION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN CARCINOMAS 
OF THE UPPER GASTROINTESTINAL TRACT
Heinz Höfler
Institute of Pathology, Technical University München, Trogerstr. 18, 81675 München, Germany
Multimodal treatment protocols are increasingly employed to improve the survival of patients with locally advanced 
adenocarcinomas of the upper gastrointestinal tract. However, only 30–40 %y of patients respond to 5-FU and cis-
platin based neoadjuvant chemotherapy. The goal of our studies is identification of reliable genetic markers, on the 
genomic DNA-level, mRNA or protein level, that can predict the response of upper gastrointestinal carcinomas prior 
to neoadjuvant chemotherapy.
In esophageal carcinomas, a higher gene expression of methylentetrahydrofolate reductase (MTHFR), an enzyme 
involved in folate metabolism, is more frequently found in responsive patients. In addition high gene expression of cal-
desmon and of the two drug carrier proteins, MRP1 and MDR1 is associated with response to therapy. By performing 
a genomwide profiling at the protein level in a small group of patients, new potential markers were identified, which 
have to be validated in ongoing studies.
In gastric carcinomas, mutations of the p53 gene revealed no association with treatment response or survival but 
tumours with a high rate of loss of heterozygosity determined by microsatellite analysis showed a better response to a 
cisplatin-based chemotherapy. Analysis of expression of 5FU- (TS, DPD, TP) and cisplatin- (ERCC1, ERCC4, GADD45A, 
KU80) related genes, demonstrated an association of DPD expression with response and survival. Consideration of 
the combined TP and GADD45 gene expression, provided the most obvious association with therapy response in 
this tumor type.
Our studies point to promising markers with potential use in chemotherapy response prediction of adenocarcinomas 
of the upper gastrointestinal tract but prospective studies for validation are necessary.
INTRODUCTION AND OBJECTIVE
Multimodal treatment protocols are increasingly 
employed to improve survival in patients with locally ad-
vanced adenocarcinomas of the esophagus and stomach. 
Neoadjuvant chemotherapeutic treatment, mainly based 
on cisplatin and 5FU, has been used since 1989 in sev-
eral clinical trials and recently a statistically significant 
improvement in: progression-free and overall survival in 
operable gastric and lower esophageal cancer has been 
demonstrated in a large randomized, controlled phase III 
trial (MAGIC trial)1. However, only 30–40 % of patients 
respond to therapy and the majority of patients undergo 
several month of toxic, expensive therapy without survival 
benefit. In particular, in the case of esophageal carcino-
mas, it has been shown that patients with non-respond-
ing tumors seem to have an even worse prognosis than 
patients treated by surgery alone, which may be related to 
therapy-induced side effects, selection of chemotherapy-re-
sistant, more aggressive tumor cells and delay in surgery2. 
Thus, identification of reliable genetic markers that can 
predict response is in high demand.
Several molecular markers have been investigated as 
potential response predictors. Thymidylate synthase as the 
target enzyme for 5-FU has been widely studied for 5FU 
containing regimens in gastrointestinal cancer but the re-
Heinz HÖFLER, MD
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and Head of the Department of Pathology at the GSF (Munich-Neuherberg). He was trained 
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Histochemistry (1991–1993), President of the German Society of Pathology (1999–2000). 
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rently Editor in Chief of Virchow’s Archive. In addition to his administrative and diagnostic 
activities Professor Höfler has published over 430 full scientific peer reviewed papers and 
several books/chapters (14). His main interest in pathology is GI and molecular pathology. He is currently acting 
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sults are inconsistent3–5. Dihydropyrimidine dehydroge-
nase (DPD) and thymidine phosphorylase (TP) are two 
other important regulatory enzymes involved in the deg-
radation of 5FU and low levels of DPD have been shown 
to be associated with response in gastric carcinoma5, 6, 
whereas conflicting results have been reported for TP.
The other major component used for the treatment of 
carcinomas of the upper gastrointestinal tract is cisplatin, 
which supposedly directly damages DNA. A significant 
association of the gene expression of the nucleotide exci-
sion enzyme ERCC1 which is involved in DNA repair, 
with response to neoadjuvant chemotherapy has been 
reported4.
Other markers such as glutathione S-transferase vascu-
lar endothelial growth factor and apoptosis-related genes 
such as bcl-2, bax and p53 have mostly been studied by 
immunohistochemistry but the results have been incon-
clusive. The result is that no markers have been found to 
be clinically relevant to date3, 7.
Thus the goal of our studies was to identify effective 
molecular markers for response prediction in patients with 
esophageal and gastric carcinomas treated by neoadjuvant 
chemotherapy. We used different strategies based on the 
one hand, on targeted approaches to characterize pre-
therapeutic biopsies for tumor specific molecular altera-
tions in genomic DNA and mRNA-level. We also analysed 
constitutional genetic factors, e.g DNA-polymorphisms in 
therapy related genes. On the other hand, we performed a 
genomwide profiling on the protein level to identify new 
marker proteins.
RESULTS
Characterization of pretherapeutic biopsies of esophageal 
carcinomas
Analysis of m-RNA expression of therapy-related genes
In this study, paraffin-embedded, formalin-fixed en-
doscopic esophageal tumor biopsies of 38 patients with 
locally advanced esophageal adenocarcinomas (Barrett’s 
adenocarcinoma) were included. All patients underwent 
two cycles of cisplatin and fluorouracil (5FU) therapy 
with or without additional paclitaxel followed by abdomi-
nothoracic oesophagectomy. RNA expression levels of 
5-FU-metabolism associated genes Thymidylate Synthase, 
Thymidine Phosphorylase, Dihydropyrimidine Dehydro-
genase, Methylenetetrahydrofolate Reductase, MAP7, 
ELF3, as well as of platinum and taxane related genes 
Caldesmon, ERCC1, ERCC4, HER2-neu, GADD45 and 
multidrug resistance gene MRP1 were determined using 
real-time RT-PCR. Expression levels were correlated with 
response to chemotherapy histopathologically assessed in 
surgically resected specimens.
The results demonstrated that the responding patients 
showed significantly higher pretherapeutic expression 
levels of MTHFR (p = 0.012), Caldesmon (p = 0.016), 
MRP1 (p = 0.007). In addition, patients with high pre-
therapeutic MTHFR and MRP1 levels had survival ben-
efit after surgery (p = 0.013 and p = 0.015, respectively)8. 
Additionally, investigation of intratumor heterogeneity of 
gene expression of relevant genes (MTHFR, Caldesmon, 
Her2-neu, ERCC4, MRP1) – verified in 9 untreated Bar-
rett’s adenocarcinomas by examination of 5 distinct tu-
mor areas – revealed no significant heterogeneity in gene 
expression indicating that expression profiles obtained 
from biopsy material may yield a representative genetic 
expression profile of total tumor tissue8.
Thus, in conclusion, the results indicate that determi-
nation of mRNA levels of a few genes may be useful for 
predicting the success of neoadjuvant chemotherapy in 
individual cancer patients with locally advanced Barrett’s 
adenocarcinoma.
Differential quantitative ProteoTope analysis of fresh 
frozen biopsies
A comprehensive protein profiling approach, using 
the ProteoSys platform, has been performed to date 
for a small group of patients. Quantitative and qualita-
tive protein expression analysis was performed using 2D 
ProteoTope techniques after radioactive labelling of the 
protein extract with I-125 and I-131. The results so far 
point to an interesting group of proteins which may be as-
sociated with response. Validation of specific proteins by 
immunhistochemical analysis in a high number of cases 
is now part of ongoing studies.
Characterization of pretherapeutic biopsies 
of gastric carcinomas
Microsatellite analysis and p53 mutation analysis
We evaluated microsatellite instability (MSI) and loss 
of heterozygosity (LOH) in 53 pretherapeutic gastric 
carcinoma biopsies using 11 microsatellite markers. The 
entire coding region of the p53 gene (exons 2 -11) was 
analyzed for mutations by DHPLC (denaturing high pres-
sure liquid chromatography) and sequencing. P53 pro-
tein expression was evaluated by immunohistochemistry. 
Patients were treated with a cisplatin-based, neoadjuvant 
chemo-therapy regimen. Therapy response was evaluated 
by CT-scan, endoscopy and endoluminal ultrasound9, 10.
We identified p53 mutations in 19 of the 53 (36 %) an-
alyzed tumors. No significant association with response or 
survival was found for p53 mutation or for p53 protein ex-
pression. Microsatellite instability (either MSI-H or MSI-
L), showed no correlation with response. With respect to 
LOH, LOH at chromosome 17p13 showed a significant 
association with therapy response (p = 0.022), but this 
did not reach statistical significance in terms of patient 
survival. The global LOH rate, expressed as fractional al-
lelic loss (FAL) was assessed and tumors were classified 
into tumors with a high (> 0.5), a medium (> 0.25–0.5) 
and a low (0–0.25) FAL-value. A statistically significant 
association of FAL with therapy resoponse was found 
(p = 0.003), with a high FAL being related to therapy 
response.
Thus, a high level of chromosomal instability (high 
FAL-value) defines a subset of patients who are more 
likely to benefit from cisplatin-based neoadjuvant chemo-
therapy. p53 mutation status is not significantly associ-
12 
ated with therapy response and is not a useful marker for 
response prediction9, 10.
Methylation analysis
We investigated the methylation profile of six genes, 
which are frequently methylated in gastric cancer (14-3-
3o, E-cadherine, HPP1, Lysyl oxidase, MGMT and p16) 
for an association with response and survival in a set of 
61 neoadjuvant treated gastric cancer patients by bisulfite/
methylation specific PCR using the TaqMan system. 46% 
of the patients showed tumor specific methylation signals 
in four or more genes. There was no significant correlation 
of response with global methylation status or with any of 
the genes alone. Patients with a low methylation status 
showed a tendency to respond to therapy and patients 
with no or only one methylated gene demonstrated a sta-
tistically significant better survival (p = 0.027). This inter-
esting finding raises the question if the use of inhibitors 
of DNA methylation and/or histone deacetylase inhibi-
tors would represent a therapeutic alternative for gastric 
cancer patients demonstrating a high methylation status 
in their tumors11.
Analysis of m-RNA expression of therapy-related genes
For gastric carcinomas we performed gene expres-
sion analysis, focussing on genes related to the effects 
of 5FU or cisplatin. Pretherapeutic, formalin-fixed and 
paraffin-embedded biopsies of 61 patients, who received 
a 5-FU and cisplatin based chemotherapy were included. 
The expression of the 5-FU related genes TS, DPD and 
TP and of the cisplatin related genes ERCC1, ERCC4, 
KU80 and GADD45Α were analyzed by quantitative real-
time PCR. The expression levels of single genes and of 
various combinations were tested for an association with 
response and overall survival5. High DPD levels were 
more frequently found in nonresponding patients and 
were associated with worse survival. GADD45Α and TP 
levels demonstrated weak associations with response, 
but GADD45Α expression correlated with survival. There 
was no association with response for TS expression, but 
tumors with a high TS-level were associated with worse 
survival. The combination of GADD45Α and TP revealed 
the strongest predictive impact. High expression values 
of TP and/or GADD45Α were exclusively found in nonre-
sponding patients (p = 0.002) and were associated with a 
significantly poorer survival (p = 0.04).
Thus in conclusion, the combined gene expression lev-
els of TP and GADD45Α represent a new parameter for 
predicting clinical outcome after neoadjuvant chemother-
apy in gastric cancer. The association of DPD expression 
with response and survival underlines the predominant 
role of DPD in predicting 5-FU sensitivity. The associa-
tion of TS expression levels with survival, but not with 
response, suggests the importance of this gene for tumor 
progression5.
OUTLOOK
Although some of our studies point to promising mark-
ers with potential use in chemotherapy response predic-
tion for adenocarcinomas of the upper gastrointestinal 
tract, prospective studies for validation are necessary be-
fore they can be used in clinical practice. As chemother-
apy response is considered highly complex, depending on 
tumor-specific characteristics as well as on the constitu-
tional genetic makeup of the individual patient, integrative 
approaches for response prediction may be necessary. In 
addition the incorporation of early response evalution by 
positron emission tomography (PET) for the therapeutic 
decision together with molecular markers, might result in 
superior sensitivity and specificity for successful applica-
tion of individual therapy-strategies in patients with upper 
gastrointestinal malignancies.
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MOLECULAR PATHOLOGY OF DNA DAMAGE CHECKPOINTS AND CANCER
Jiri Bartek
Danish Cancer Society, Copenhagen, Denmark
e-mail: jb@cancer.dk
The lecture will provide a brief outline of our most re-
cent work on mechanisms of cell cycle control and DNA 
damage responses in mammalian cells, with emphasis on 
the following specific issues and their potential implica-
tions for the fields of molecular pathology, mechanisms 
of oncogenesis and cancer therapy. First, the emerging 
biological differences between the ATR-Chk1-regulated 
and ATM-Chk2-regulated pathways in unperturbed cell 
cycles and in response to genotoxic insults will be dis-
cussed. This part will include presentation of our results 
on the functional assessment of DNA damage signaling 
and effector pathways directly in human biopsy material, 
as well as data on new roles and substrates of Chk1 kinase 
and consideration of Chk1 kinase inhibition as a potential 
strategy to sensitize cancer cells to DNA damaging treat-
ment modalities. Second, our data supporting a concept 
of the DNA damage response machinery as an inducible 
barrier against progression of early stages of human tu-
mours in vivo, and in response to various oncogenes in 
cell culture models, will be presented. Here, emphasis will 
be mainly on unpublished results on distinct patterns of 
DNA damage response activation seen in diverse types of 
human malignancies, discussion of the potential cellular 
and molecular basis of such differences, as well as the 
role of genetic and epigenetic defects in the DNA dam-
age response machinery in the predisposition to familial 
cancer. The lecture will finish by demonstrations of the 
most recent techniques that allow us to analyze these sig-
naling and checkpoint mechanisms in real time, directly 
in live human cells.
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THE CHANGING WORLD OF THE PATHOLOGIST
Yrjö Collan
Department of Pathology, University of Turku, Finland
The pathologist used to be considered as a helper of 
the clinician. The clinician’s main job was to find the best 
management and treatment for the patient. The patholo-
gist worked in his laboratory, or in the autopsy rooms, 
and served the clinician with diagnoses, on the basis of 
which clinical decisions could be made, and explanations 
given to relatives. Today, this basic arrangement is chang-
ing. One of the reasons is the dramatic diversification 
of medicine. New knowledge is generated from many 
sources. Especially important in this general context is 
the expansion of therapy options, and the development 
of new drugs which often need evaluation from the pa-
thologist so that they can be used optimally. This is im-
portant not only from the medical point of view, but is 
also important economically, as the newest drugs are of-
ten the most expensive ones. For the efficient use of new 
information and for the election of the right treatment 
options clinical therapy selection meetings are common, 
and the pathologists have an increasingly active role in 
these. The pathologists of today should feel that they, too, 
are representatives of patients. Only through this means 
can clinical meetings fully benefit from the results of the 
pathology department.
To understand the present situation and future de-
velopments we have to look back. The generation which 
studied medicine in the 1960’s is starting to retire. Since 
those days medical knowledge base has expanded dramati-
cally, and not only through the development within medi-
cine, but also through the development in biology, and 
especially through the newest field of biology, molecular 
biology. What knowledge in pathology and genetic pathol-
ogy were medical students taught then in the 1960’s? A 
look at the textbook of pathology by William Boyd1 can 
provide an answer.
In 1952 the Watson – Crick model of DNA structure 
was published, and this information was already in the 
pathology textbook, and clearly the model has influenced 
the thinking in pathology. The textbook also described the 
knowledge base of genetics quite well and referred espe-
cially to the works of Mendel and Morgan. The concept of 
aneuploidy was mentioned in contrast to euploid number 
of chromosomes or amount of DNA. The importance of 
mutations was also mentioned. Four basic types of in-
heritance were listed (autosomal dominant, autosomal 
recessive, modified autosomal, sex-linked inheritance). 
Chromosomal abnormalities were known to exist and 
Turner’s syndrome (44 X0) and Klinifelter’s syndrome 
(44XXY) were listed. The carcinogens were listed quite 
thoroughly (chemicals, radiation, viruses, hormones, en-
vironment & occupation, co-carcinogens) but a general 
unifying theory was lacking. In fact those were the days 
when there was a conceptual fight between chemical car-
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cinogenesis and viral carcinogenesis: nobody really dared 
to say which was the most important in human cancer. 
In line with the lack of unified theory of carcinogenesis 
there was no talk of oncogenes or tumor suppressor genes, 
which emerged through the development of molecular 
biology. Many hereditary diseases were mentioned and 
the concept of inborn error of metabolism was clearly 
presented. The clinical genetics was shaping itself those 
days, and the still continuing work of McKusick (OMIM, 
www.ncbi.nlm.nih.gov) was in its early phases. Numer-
ous genetic diseases were listed (haemophilia, sickle cell 
anemia, Gaucher’s disease, Nieman-Pick disease, Wilson’s 
disease, glycogenoses, phenylketonuria, renal tubular de-
fects, cystinuria, gout, and many hereditary skeletal de-
fects, neuromuscular diseases, skin diseases, eye diseases, 
mental and neurological diseases) were mentioned. Even 
hereditary types of colorectal carcinoma were mentioned. 
It was more or less clear from the pages of the textbook 
that there was only a limited help available to patients 
suffering from most of these diseases.
If one looks at more specific textbooks on genetics 
published in the 1960’s, one cannot help admiring the 
achievements which were already there before the time 
of molecular medicine. Molecular genetics was very ad-
vanced, especially in virology. Its medical relevance only 
was much less than today.
The difference between Boyd’s textbook and that ed-
ited by Underwood2 in 2004 is obvious. In addition to 
the more impressive type of printing work and extensive 
editing, the new information on molecular biology (or in 
this context, molecular pathology) clearly shapes the text. 
The genomic theory of carcinogenesis best outlined by the 
groups of Varmus and Weinberg is in substance presented 
in the text. This textbook stresses the difference between 
genetic and environmental causes of diseases, and the 
influence of the interplay of these causes in the actual 
situation of the patient. The structure of genes is clearly 
described, and concepts earlier unknown, like reverse 
transcription, explained and put in context of pathology. 
The importance of gene polymorphisms in disease is out-
lined. Numerous genomic changes not listed in the 1960’s 
are outlined. The landmarks of the development of mo-
lecular biology are similarly outlined. Growth factors and 
intra- and extracellular mediators are listed and described 
in connection with inflammation, immunopathology and 
carcinogenesis. The thinking associated with molecular 
therapy is introduced. Apoptosis and its regulators are 
studied. The molecular changes associated with genetic 
disease are explained and shown in a few examples (like 
cystic fibrosis). The complex systems of mediators and 
adhesion molecules of immunity are outlined. Oncoge-
netic mechanisms are explained in many conditions on 
the basis of available information from molecular pathol-
ogy. In line with the extended knowledge the textbook 
serves for becoming physicians, the pathologists are today 
served with classifications which include morphological 
and genomic information. This approach is now in WHO 
tumor atlases3, which stress the importance of molecular 
pathology and genomic information in the work of the 
pathologist.
It is now absolutely clear, that molecular pathology is 
indispensable to the training of that pathologists to meet 
the challenges of the future. However, we have to under-
stand that it is not only molecular pathology which we 
have to understand. We also need the understanding of 
traditional methodology. This much stresses the fact that 
we have to see the pathology discipline as a discipline in 
which thorough and continuous education is vitally im-
portant. Time, space, opportunities, and money should be 
given for pathologists to participate in continuous train-
ing.
It is a great mistake to think that development is not 
taking place in other fields than molecular pathology. 
We have to be knowledgeable about these developments 
too.
Light microscopy is the most important and basic 
method in histopathology. In tumor diagnosis light mi-
croscopy gives the basic background knowledge for diag-
nosis. What is normal and what is normal in relation to 
age is often more important than the exact knowledge of 
the classification of finding. Classification after the first 
examination under light microscope can be and probably 
should always be studied from books. The use of updated 
books is especially important in pathology.
A couple of years ago nobody could imagine that 
light microscopy could change in other respects than in 
ergonomy or improved optics. However, through digital 
imaging, and the methods of virtual microscopy we are 
today in a situation in which the traditional microscopy 
is no longer necessary. That means that the pathologist 
does not necessarily need a microscope in front of him 
As a basic solution to virtual microscopy the department 
has a microscope which scans all the sections produced 
by the histopathology laboratory to make digital images. 
Scanning is done on high power so that the number of 
pixels presenting the whole slide can be enormous. Such 
presentation, however, will allow evaluation of the image 
at low power on the computer screen, and allow zooming 
into areas which look interesting. In fact this is micros-
copy done on the computer screen, without a microscope 
in the hands of the pathologist, and called virtual micros-
copy. Because in this arrangement the slide is transformed 
into an image presented by electrical signals, the image 
can be transferred long distances through the internet. 
The pathologist of the future does not need to do his work 
at the microscope, and he can be consulted when abroad, 
and he can even do his work – in theory – while being 
on holiday. There is evidence that the pathology commu-
nity is not yet completely ready for this change, but it is 
clear that virtual pathology is rapidly coming, especially in 
consultation over long distances, medical education, and 
pathology training. It is clear that the training pathologists 
should learn about virtual microscopy.
Electron microscopy has become an important re-
search method. Clinical applications, however, are today 
more limited than the most optimistic predictions once 
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suggested. This is only partly associated with the limits 
of the method itself. The method is more laborious than 
immunohistochemistry and needs more intense participa-
tion by the pathologist than immunohistochemistry. How-
ever, many pathologists still feel that at least in problem 
cases electron microscopy of tumors is helpful. However, 
there are areas, in which electron microscopy has been 
incorporated in the diagnostic protocol, and as part of 
the protocol serves the diagnostics well. The best example 
is kidney biopsy diagnosis, in association of which the 
diagnostic process benefits in about 70 % of biopsies4, 
either by showing positive diagnostic association, or by 
excluding disease entities. So, for covering diagnostic 
process electron microscopy in kidney biopsy diagnosis 
is essential, yet, it is much less utilized in tumor diagnosis. 
It is clear, that electron microscopy should be part of the 
training among training pathologists.
Enzyme histochemistry, which is used for locating spe-
cific enzymes in tissues through the reactions they them-
selves activate, has today limited value in the diagnostic 
process, but not totally forgotten, as shown by the tartrate 
resistant acid phosphatase in the diagnosis of hairy cell 
leukaemia5. However, histochemistry associated with tra-
ditional stains is diagnostically more important. Congo 
stain, of course, is an example, as it detects the various 
types of amyloid proteins. It is clear that the chemistry 
theory associated with staining, and the principles of his-
tochemistry should be part of pathologist’s training.
Quantitative pathology including DNA cytometry has 
become more popular than it used to be. Mitotic counts 
(e.g. in producing reliable histological grade in breast 
cancer) are important, and often have dramatic prognos-
tic value6, but also morphometric methods are valuable. 
DNA cytometry has much potential, and should be prac-
ticed more than it is practiced today. Much basic research 
with this method will be necessary in grouping tumors 
which potientially can be treated with newly developed 
drugs. Quantitative pathology training among patholo-
gists is clearly insufficient. Much theoretical and practical 
diagnostic knowledge can be gained through courses on 
quantitative pathology.
Immunohistochemistry and molecular pathology 
clearly overlap. One can detect the expression of certain 
genes by detecting the presence of the transcribed mes-
senger RNA (mRNA) by in situ hybridisation or other 
means. However, immunohistochemistry for detecting the 
corresponding translated protein is much more widely 
practiced. This area has developed fast and is still devel-
oping in the histopathology laboratory. The diagnostic 
value of immunohistochemistry is immense, to the degree 
that immunohistochemistry changes the classifications, 
and changes the interpretations of classifications in our 
everyday work. It is quite normal that the histopathol-
ogy laboratory of a university hospital uses more than 
100 antibodies for detecting a corresponding number of 
antigens in association with the daily diagnostic work. It 
is here that the diagnostic emphasis is today, especially in 
association with tumor classification. Pathologists should 
be trained thoroughly in immunohistochemistry, both in 
theory, laboratory practice, and interpretation. The meth-
ods of quantitative pathology in the interpretation can be 
especially fruitful.
It is difficult to predict how the science of pathology 
will develop. Some points are clear, however. Immuno-
histochemistry will still increase in importance for a long 
time. Molecular pathology is gaining importance daily. 
Traditional laboratory methods will stay for a long time, 
because morphology is so important, especially in tumor 
diagnosis. Quantitative methods will be introduced in all 
fields of pathology because they improve the accuracy of 
the diagnostic process. Virtual microscopy will become 
more commonly practiced than it is practiced today. Elec-
tron microscopy will stay at least in kidney biopsy diagno-
sis. DNA cytometry may give help in tumor diagnosis, but 
its role will be much dependent on whether this method 
is also studied in association with drug studies. But one 
aspect is certain: If any field of medicine, pathology will 
be the field of a life long study. The medical community 
should realise this, and we, as pathologists should keep 
an open mind towards scientific development.
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NODAL STAGING OF BREAST CANCER VIA SENTINEL NODE BIOPSY
Gábor Cserni
Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary
Sentinel lymph node biopsy (SLNB) has gained a lot 
of interest in the staging of solid malignancies. In connec-
tion with breast cancer, it was first reported in the early 
nineties1–3, and was claimed to represent a tool for a more 
reliable staging4.
There have been many controversies concerning the 
optimal histological assessment of the SLNs. Some of the 
early reports documented a standard histological work-
up, whereas others used enhanced pathology5. In routine 
practice, the SLNs are usually subjected to more detailed 
evaluation than other lymph nodes6, and this may raise 
the question of whether or not the upstaging rate of SLNB 
derives simply from differences in methods used for the 
SLNs and the non-SLNs. A few studies have compared 
the yield of enhanced histopathology for both SLNs and 
non-SLNs, and have shown that the SLNs are indeed the 
most likely sites of regional nodal metastases7–11. By using 
an enhanced histopathology consisting of a combination 
of multilevel assessment and immunohistochemistry for 
epithelial markers, the upstaging rates vary between 9 and 
47 % (Ref.12), and this rather large range is principally 
explained by differences in methods.
Molecular methods of nodal staging have been studied 
by several groups. Their use should result in ultrastaging 
of breast carcinomas, as it seems that both RT-PCR assays 
and flow cytometry are more sensitive than microscopic 
methods for metastasis detection12. Despite the fact that 
this conference is about novel techniques and concen-
trates on molecular pathology, the participants should 
not be misled in this respect. Molecular nodal staging is 
sensitive but we cannot neglect microscopic checking at 
present. Most series I know about have found at least a 
few cases that were positive by microscopy and negative 
by the molecular assay used11 – these should obviously 
by classified as node-positive. On the other hand, those 
cases that have only molecular marker positivity and 
lack histological evidence for nodal involvement should 
be classified as node-negative for staging and treatment 
purposes13–16.
Based on the weakest level of evidence, experts’ 
opinion and review of available data11, what constitutes 
standard evaluation of SLNs is a method that can identify 
all macrometastases and preferably all micrometastases 
too16, 17. Cytokeratin immunohistochemistry may be a part 
of the analysis, especially for lobular carcinomas18, but 
molecular nodal analysis still represents an area of re-
search despite the fact that positivity coincides with mark-
ers of poor prognosis19.
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Although in comparison to breast, lung and colon 
cancer, the brain is a relatively uncommon site for the 
development of cancer, the brain is the tenth most com-
mon site for the development of cancer in men and about 
the twelfth in women. This translates to about 6,000 indi-
viduals in the UK developing a primary malignant brain 
tumour every year. Cancer of the brain develops in two 
distinct age groups, although the types of tumour that 
develop in these two age groups differ markedly. There is 
a peak of incidence in the first decade of life, and brain 
tumours rank with leukaemia as a leading cause of can-
cer death in children. These tumours tend to be indolent 
low-grade astrocytomas or highly malignant primitive neu-
roectodermal tumours like medulloblastoma. However, 
the vast majority of brain tumours occur with increasing 
frequency in the sixth, seventh and eight decade of life 
and they are the second fastest growing cause of cancer 
death among those over 65. These tumours tend to be 
malignant astrocytomas particularly the most malignant 
variety, glioblastoma multiforme (GBM). Unlike lung can-
cer or malignant melanoma there is no strong evidence 
of an environmental carcinogen associated with the de-
velopment of these tumours and no change in behaviour 
reduces risk.
The commonest malignant brain tumours in adults 
are derived from the supporting glial cells in the brain 
(Rampling et al., 2004). These tumours, known collec-
tively as glioma, include tumours derived from astrocytes, 
astrocytomas; from oligodendrocytes, oligodendroglioma; 
and the ependymal cells that line the cerebral ventricles, 
ependymoma. In practice, the vast majority of primary 
brain tumours are derived from astrocytes. These tu-
mours display a wide variation in malignant potential, 
ranging from low grade astrocytomas that, although they 
display in adults a marked propensity for malignant pro-
gression, have median survivals measured in decades to 
highly malignant tumours like glioblastoma multiforme 
(GBM) where the median survival is of the order of 9–12 
months.
The histological features that are characteristic of 
GBM are marked nuclear atypia and mitotic activity, ar-
eas of necrosis bordered by areas of glial cells displaying 
characteristic pseudopallisading and significant evidence 
of endothelial proliferation. A further hallmark is that 
there are always both within different areas of the same 
tumour and between different GBMs marked heterogene-
ity in histological and cytological appearance. Although it 
is clear that GBMs are monoclonal tumours the cellular 
heterogeneity, presumably a result of significant genetic 
instability, suggests that there is likely to be considerable 
complexity in terms of therapeutic response between dif-
ferent parts of the tumour. Perhaps as a consequence 
of this cellular heterogeneity there is often considerable 
variation in the survival of patients with these malignant 
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tumours. Whilst it is true that the median survival may 
be of the order of 9–12 months, many clinical trials have 
shown that there is a proportion of patients (perhaps of 
the order of 10–15 %) who derive disproportionate benefit 
from the radiotherapy and adjuvant chemotherapy that 
they receive. It is from this group of patients that now a 
significant minority of patients with GBM survive 2 to 3 
years from diagnosis. Although clinical features like age 
and performance status are powerful prognostic factors 
in patients with GBM, it seems reasonable to assume that 
biological features of the tumour also influence survival. 
There certainly seem to be two major types of GBM in 
adults that have different patterns of genetic changes. The 
most common variety is primary GBM that appears to 
arise de novo with signs or symptoms extending only a 
few months or weeks and no evidence of a pre-existing 
tumour. Typically these tumours do not have p53 muta-
tions but often express a mutated form of the epidermal 
growth factor receptor (EGFR). On the other hand, there 
are those cases of GBM that arise as a result of malignant 
transformation of a low-grade astrocytoma. These second-
ary GBMs do not typically express altered forms of the 
EGFR but commonly do have p53 mutations. However, 
once the tumour has progressed to GBM, there is no sys-
tematic evidence of a difference in survival between these 
two groups of GBM patients. One feature that is common 
to the two groups of GBM is the presence of abnormali-
ties on chromosome 10 that seem to be obligatory for 
the development of the GBM phenotype. However, we 
have been able to show that GBM in children and young 
adults (<25 years old) does not conform to this scheme. 
In a series of 10 young patients with GBM we have been 
able to identify a wide variety of genomic imbalances. The 
most common recurrent copy number aberrations were 
loss of 16p (54 % of cases), 17p (38 %), 19p (38 %), and 
22 (38 %) and gain on 2q (38 %), 12q (38 %), 13 (38 %), 
4q (31 %), 5q (31 %), and 8q (31 %). Seven regions of 
high copy number amplification were observed at 8q21-22, 
7q22-23, and 1p21-22, 2q22, 12q13-pter, 12q15-21, and 
13q11-14. In other words, the common genetic changes 
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in adult GBMs are not features of GBM in children and 
young adults and vice versa. Of course the aim of studies 
like this is actually to produce data that is of clinical rel-
evance in individual cases. For example, can we identify 
molecular signatures that are predictive of long-term sur-
vival or response to particular cytotoxic drugs? There are 
some tantalising data that suggests that certain genomic 
changes are associated with long-term survival in patients 
with GBM. Burton and colleagues (2001a,b) have report-
ed that losses of chromosome 9p and 10 and gains of 19q 
were associated with poor survival and that 19q loss was 
restricted to long-term survival (i.e. those GBM patients 
who survived longer than 3 years from diagnosis). Inter-
estingly, p53 mutation and aberrant expression of p53 
protein was also associated with longer survival (Schmidt 
et al., 2002). This suggests that p53 disruption might be 
associated with long-term survival. We have analysed the 
relationship between p53 mutation and chemosensitivity 
in short-term cultures derived from GBM biopsy samples. 
In this system, there is a marked relationship between p53 
mutation and sensitivity in vitro to two drugs used clini-
cally to treat patients with GBM, CCNU and vincristine 
(Ashmore et al., 2006). A recent study has indicated that 
using expression microarrays, clinically meaningful sub-
groups can be identified (Liang et al., 2005). However, a 
drawback with many of these studies is that the number 
of patients included in these studies is small and the exact 
therapies individuals received is unclear. This precludes a 
definitive analysis of the relationship between molecular 
changes and outcome in individual cases.
A clearer indication of the clinical utility of using 
molecular genetics to detect sub-groups of brain tumour 
patients that are likely to respond to particular cytotoxic 
drugs comes from patients with oligodendroglioma. These 
are rare tumours and most are well differentiated with 
little evidence of proliferative activity. However about a 
third of patients present with a anaplastic variant which 
displays aggressive features like increased mitotic activity, 
nuclear pleomorphism and vascular proliferation. Over 
the last fifteen years it had become clear that about 70 % 
of these malignant oligodendroglioma responds to com-
bination chemotherapy with procarbazine, CCNU and 
vincristine (the PCV protocol) and consequently have a 
considerably more favourable prognosis than patients with 
malignant astrocytoma. The apparent chemosensitivity of 
anaplastic oligodendroglioma appears to be associated 
with loss of sequences on chromosome 1p and 19q. It is 
unclear which genes are responsible for this. Are there 
specific genes that are lost in these tumours that produce 
chemosensitivity or does this represent the identification 
of two types of tumour, one sensitive and one not chemo-
sensitive but with the same histological appearance?
The relative ease with which samples of GBM produce 
short-term cell lines composed of replicating neoplastic 
glial-like cells and eventually established cell lines provides 
a powerful model system for investigating the relationship 
between molecular features and therapeutic sensitivity. 
The relationship between p53 mutation and sensitivity 
to cytotoxic drugs has been mentioned above. We have 
developed a panel of sixteen short-term cell lines derived 
from surgical biopsies and have been characterising the 
phenotype and genotype of these cultures in relation to 
response to cytotoxic drugs. A striking feature is the very 
complexity of the drug resistance mechanisms that can 
be identified in these cultures. In addition to the p53 sta-
tus of these cell lines we have investigated the expression 
of O6-methylguanine DNA methyltransferase (MGMT) 
together with the methylation status of its promoter, cy-
togenetic profile, expression of drug transport molecules, 
“stem cell” content and the NF-KappaB status. It is clear 
that multiple drug resistance mechanisms are present in 
a single cell (Figure 1). This very complexity in a com-
paratively simple situation in vitro is no doubt responsible 
for the difficulties there have been in correlating molecu-
lar changes and response to therapy in clinical studies. 
Nevertheless, such in vitro experiments will provide the 
background for properly designed clinical studies to be 
developed in the future.
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RE-EXPRESSION OF INTERMEDIATE FILAMENT NESTIN IN ADULT TISSUES
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We examined immunohistochemical expression of intermediate filament protein nestin in paraffin-embedded 
sections of rat and human tissues. During prenatal development, nestin expression was mainly confined to nervous, 
muscular and cardiovascular systems with no major inter-species differences in its cellular distribution. In intact 
adult tissues, nestin expression was down-regulated and the protein was detected only in the immature cells that were 
generated to balance tissue homeostasis. We concluded that in these systems, nestin could be considered a reliable 
developmental marker that allows us to distinguish undifferentiated from mature cells. Finally we examined whether 
IF nestin was re-expressed in adult tissues affected by disorders associated with cell growth such as neoplasia and re-
generation. We focused on tumours derived from nervous tissue and samples tissue affected by myocardial infarction. 
High and consistent levels of nestin expression were observed in high grade astrocytomas, malignant melanoblastomas 
and capillary haemangiomas. In these tumours, nestin detection may help us in precise classification of tumours and 
might be also used as a predictive factor. In all specimens of myocardial infarction, intermediate filament nestin was 
re-expressed in cardiomyocytes and capillaries providing evidence that nestin could be a novel and invaluable marker 
in studies of the pathogenesis of heart diseases.
INTRODUCTION
The class VI intermediate filament protein nestin was 
named according to its abundant expression in neuroepi-
thelial stem cells (nestin is an acronym for neuroepithelial 
stem cell protein)1. However nestin was also found to be 
expressed in other cells of neural origin2,3,4. Outside the 
nervous tissue, high levels of nestin were detected in the 
developing skeletal and cardiac muscle1,2,5,6,7. Another type 
of cell that expresses nestin is the immature endothelial 
cell8. Expression of nestin in nervous tissue is controlled 
by the second intron of the nestin gene whereas its expres-
sion in muscle precursor- and endothelium-specific regula-
tors was identified in the first intron of the gene9,10.
In most cases, the nestin gene is expressed in undif-
ferentiated cells and is down-regulated in postmitotic 
differentiated cells, being replaced with another type of 
intermediate filament6,11. As a result, nestin can be consid-
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ered a remarkable developmental marker that is expressed 
in early phases of ontogenesis. In lost cells adult tissues, 
nestin appears in immature cells that are produced to 
replenish or in dedifferentiated cells produced during tum-
origenesis, e.g. in brain tumours4,12. Thus temporary nestin 
expression is induced under situations that correspond to 
recapitulation of developmental phases.
In this study, we examined immunohistochemical ex-
pression of nestin in archival material of rat and human 
tissues. The specimens were taken from embryonic as well 
as intact adult tissues and their examination showed no 
inter-species differences in protein localization. To judge 
whether nestin immunodetection could be exploited as a 
useful marker in human histopathological diagnosis we 
focused on disorders affecting the central nervous and car-
diovascular systems because both systems are associated 
with nestin expression during neurogenesis, cardiogenesis 
and angiogenesis. Our results confirmed the usefulness of 
nestin immunodetection in the diagnostics of astrocyto-
mas, capillary haemangiomas, melanoblastomas and in 
examination of early changes that occur in the myocar-
dium after heart attack.
MATERIAL AND METHODS
For examination of both rat and human tissues we 
used archived samples fixed in 10% formalin and embed-
ded in paraffin. Pseudoperoxidase activity in deparaffin-
ized sections was suppressed in solution of 3% H2O2 in 
methanol. Revitalisation of epitopes was performed by 
pretreatment in the microwave oven. Following thorough 
washing in PBS containing 5% Triton X-100 (Sigma), 
sections were incubated with a primary antibody at 4°C 
overnight. The rat tissues were incubated with primary 
monoclonal antibody Rat-401 (DSHB, Iowa). Nestin in 
the human tissue was identified with monoclonal antibody 
10C2 (Chemicon, UK). Following washing with PBS, 
sites where primary antibody bound to nestin epitopes 
were visualized with a goat anti-mouse biotinylated anti-
body, streptavidin conjugated to horseradish peroxidase 
and diaminobenzidine (Sigma). Sections were counter-
stained with the methyl green or haematoxylin. To avoid 
false positivity, parallel sections were processed according 
to the same protocol but primary antibodies were omitted. 
To receive intense signal, some detections were not devel-
oped in diaminobenzidine but were twice amplified with 
biotinylated tyramine and visualized with streptavidin 
conjugated to fluorochrome Cy3 (Jackson ImmunoRe-
search Laboratories). Nuclei were then counterstained 
with DAPI and sections were mounted in polyvinylalco-
hol/glycerol with DABCO; for light microscopy the sec-
tions were mounted in DPX. Sections were examined in 
Olympus BX51 microscope equipped with epifluorescence 
and DP-70 camera.
RESULTS
We first concentrated on studying nestin expression in 
developing rat tissues and then evaluated whether the cor-
responding developing human tissues expressed also this 
protein. In both rat and human embryonic tissues, nestin 
was mainly localized in corresponding cells of the nerv-
ous, cardiovascular and muscular systems. In the CNS, 
nestin was found in neural stem cells, radial glial cells 
and developing astroglial cells. As astroglial cells differ-
entiated, nestin protein was redistributed to their endfeet 
processes that formed superficial and perivascular limit-
ing membranes. Nestin was also expressed by cerebral 
capillaries that were ensheathed by apposed perivascular 
astrocytic endfeet. Examination of non-neural rat and 
human tissues revealed that nestin was expressed in en-
dothelial cells of capillaries and larger blood vessels that 
grew in the developing organs. Moreover, we observed 
nestin also in extraembryonic blood vessels inside the rat 
and human placenta. The third typical structures express-
ing high levels of nestin were represented by muscular 
tissues. The smooth muscle (in developing intestines or 
arteries) showed just low levels of nestin. On the contrary, 
myoblasts and myotubes of the skeletal muscle contained 
high levels and during the skeletal muscle differentiation, 
nestin was gradually replaced by desmin. In the myocar-
dium, cardiac muscle cells in both atria and ventricles 
showed intense immunoreactivity for nestin during early 
stages of development, which is lost after maturation in 
cardiomyocytes.
Nestin expression in adult intact tissues was relatively 
rare. In the forebrain, nestin was observed in the sub-
ependymal zone and even more abundantly in the rostral 
migratory stream of rats. In the brain, the protein was also 
detected in tanycytes (especially around the third cerebral 
ventricle) and astrocytes (mainly fibrillary astrocytes and 
endfeet of those participating in formation of perivascu-
lar and superficial limiting membranes). Cerebral blood 
vessels contained nestin-positive endothelial cells spo-
radically. The same was true for other tissues including 
muscular tissues. The only exception was represented by 
those tissues, which grew in response to cyclic hormonal 
changes like the corpus luteum or endometrium. Such 
tissues contained lots of nestin-immunoreactive blood ves-
sels of different calibres. Adult intact muscular tissues 
were devoid of nestin.
Situation changed during pathological processes. In 
astrocytomas, nestin immunoreactivity appeared in some 
undifferentiated neoplastic cells, reactive astrocytes and in 
neocapillaries. High grade astrocytomas revealed higher 
histoscore than low grade astrocytomas. Nestin was also 
observed in radial-glia like elements in the meduloblas-
tomas. From other tumours, nestin was found in medu-
loepitheliomas and two-thirds of supratentorial primitive 
neuroectodermal tumours. In haemangioblastomas, im-
munoreactivity for nestin was observed in fenestrated 
capillaries and some types of stromal cells. High levels 
of nestin were observed in melanoblastoma, where all 
tumour cells expressed this protein. Moreover, blood ves-
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sels represented mainly by capillaries, found within the 
tumour or at its periphery also showed high immunoreac-
tivity. High levels of nestin were also typical for capillary 
haemangiomas where immunopositivity was found in en-
dothelial cells and pericytes. On the contrary, cavernous 
haemangiomas were nestin-negative.
Nestin elevation was also detected in adult tissues 
suffering from non-tumourigenic diseases like ischaemic 
heart disease. In patients who survived for few days after 
acute heart attack, nestin reappeared in their myocardium. 
Immunoreactivity was confined to blood vessels and also 
to cardiac muscle cells in the vicinity to necrotic areas. 
Depending on time interval from the onset of myocardial 
infarction, nestin immunoreactivity appeared in the entire 
sarcoplasm of cardiomyocytes or was reduced to subsar-
colemic areas or to intercalated discs.
DISCUSSION
Intermediate filament protein nestin confers the cell 
cytoskeleton remarkable flexibility. Nestin itself cannot 
form stable filament network but it co-polymerizes with 
type III intermediate filaments, e.g. vimentin13. Such heter-
opolymers are less stable than vimentin oligomers, which 
is essential for promotion of disassembly and restructur-
ing of the vimentin intermediate filament network during 
mitotic division and migration of progenitor cells14. As 
a result nestin expression is typical for developing cells 
and for that reason it is heavily expressed in developing 
neural, muscle or endothelial cells. As these cells differ-
entiate nestin disappears being replaced by another and 
permanent type of intermediate filament6,11. From this 
point of view, nestin can be considered as a remarkable 
developmental marker: it is expressed in early phases of 
development associated with cell proliferation and it is 
lost after cell maturation.
In adult organs, tissue homeostasis keeps the cells at 
appropriate amounts balancing well cell death and cell 
renewal to preserve tissue maintenance. Here again, pro-
duction of new cells in nervous, cardiovascular and mus-
cular systems has to be associated with nestin expression 
to provide the cell cytoskeleton properties necessary for a 
proper development in desired phenotypes. Therefore nes-
tin expression in areas of active adult neurogenesis like the 
subependymal zone or rostral migratory stream can not 
be surprising15. Similarly growing tissues like the uterine 
endometrium10, corpus luteum16 or tumours4,12,17 are char-
acteristic with nestin immunoreactivity. Nestin is confined 
to newly formed capillaries that enter the growing tissue 
or may be expressed in newly formed cells e.g. in case 
of tumours of neural origin. Nestin immunohistochemis-
try can be used for the grading of astroglial tumours and 
its expression has significant value in astrocytomas and 
malignant melanomas as an auxiliary indicator of dedif-
ferentiation and progression18.
The most surprising is nestin expression in the myo-
cardium. Although the protein is expressed during early 
phase of development, its expression in cardiac muscle 
cells in embryonic mice is limited to a short interval of two 
days7. After embryonic day 11 to adulthood, the authors 
were not able to detect nestin in the mouse myocardium. 
Since nestin expression was observed in the same cell 
types and under same physiological situations in mouse 
and human tissues, we can expect that nestin expression 
in the human heart is also confined to embryonic heart 
and it is presence disappears in intact adult heart tissue. 
Our preliminary results confirm this hypothesis. Obser-
vation of nestin+ cardiomyocytes and endothelial cells in 
samples of infarcted myocardium might correspond to the 
tissue repair. Recently identified stem cells in the myocar-
dium confirm the potential of cardiac muscle tissue for its 
regeneration19. If new cardiac muscle cells are generated 
in response to ischaemic injury, newly produced cardio-
myocytes have to be nestin+. Moreover, changes in nestin 
distribution in cardiac muscle cells are closely similar to 
those observed in developing skeletal muscle where im-
mature myoblasts and myotubes are first immunostained 
for nestin homogenously but as the skeletal fibres mature, 
nestin gradually disappears and its immunoreactivity is 
concentrated to area of motor end-plate20.
To summarize our results, we confirm that intermedi-
ate filament nestin is primarily expressed in developing 
nervous and muscular tissues and endothelial cells both 
in rodent and human tissues. As the cells differentiate, 
nestin levels decrease being substituted by permanent in-
termediate filaments proteins. However, nestin expression 
reappears in adult nervous and muscular tissues as well 
as in blood vessels when new cells are generated in the 
course of maintenance of tissue homeostasis or tumouri-
genesis. In the former case, few cells in intact tissues are 
generated in response to physiological stimuli to replace 
dead cells. Production of cells is higher in specialized 
sites of neurogenesis such as the subependymal zone. In-
crease in nestin+ cells can also be associated with increase 
in cell production during tissue reparation. In the latter 
case, nestin reappears in tumours arising from cells that 
express this protein in early phases of their ontogenesis. 
Nestin expression is characteristic for undifferentiated 
phenotypes which may be used as a predictive factor in 
histopathological evaluation of some tumours. Nestin ex-
pression in the infarcted myocardium may be associated 
with generation of new cardiac muscle and endothelial 
cells or may correspond to changes in the cytoskeleton 
of cardiomyocytes that adapt to new conditions. Further 
investigation is necessary to reveal a precise role of nestin 
in diseased cardiac muscle cells.
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CONTRIBUTION OF THE EPSTEIN-BARR VIRUS TO THE HISTOLOGICAL PHENOTYPE 
OF HODGKIN’S LYMPHOMA
Paul G Murray
Institute for Cancer Studies, University of Birmingham, B15 2TT, UK
e-mail: p.g.murray@bham.ac.uk
The Epstein-Barr virus (EBV) is a ubiquitous herpes 
virus which can establish a persistent but usually harmless 
infection in the human host following colonisation of the 
memory B cell pool. However, EBV can also contribute 
to the development of Burkitt’s lymphoma (BL), post-
transplant lymphoma, and classical Hodgkin’s lymphoma 
(HL), where it is detected in approximately half of all 
cases. HL is characterised by malignant Hodgkin/Reed-
Sternberg (HRS) cells surrounded by an abundance of 
non-malignant ‘reactive’ cells. The detection of crippling 
immunoglobulin (Ig) gene mutations in a proportion of 
HL indicates that HRS cells derive from pre-apoptotic ger-
minal center (GC) B cells that would normally have un-
dergone apoptosis. Despite their B cell origin, HRS cells 
not only lack expression of the B cell receptor (BCR) but 
also show a unique pattern of downregulation of B cell- 
and lymphoid-associated genes and surface markers.
EBV can rescue BCR-negative human tonsillar GC 
cells from apoptosis indicating that viral genes may inter-
fere with the GC reaction. Using transgenic mice models, 
the EBV-encoded latent membrane protein 2A (LMP2A) 
has been shown to enable the survival of BCR-deficient B 
cells by providing a surrogate BCR signal. The other EBV 
latent membrane protein, LMP1, mimics a constitutively 
active CD40 receptor and can promote the survival of 
CD40-deficient transgenic murine B cells. Furthermore, 
LMP1 is a potent oncogene as it transforms rodent fibrob-
lasts and is essential for B cell immortalization
Both LMP1 and LMP2A are expressed in EBV-positive 
HL, suggesting an important role for these viral proteins 
in the pathogenesis of this tumor. LMP2A expression in 
mouse B cells and in a non-Hodgkin’s lymphoma cell line 
leads to changes in gene expression resembling those seen 
in HRS cells, including downregulation of B cell lineage-
specific genes. However, the contribution of LMP1 to the 
HRS cell transcriptional signature has yet to be defined. 
Since LMP1 can redirect the transcriptional programme 
of B cells, by activating a range of signalling pathways (e.g. 
Paul G MURRAY, Dr., Ph.D. 
Paul G Murray is currently Reader in Molecular Pathology at the Cancer Research Insti-
tute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT.
The major focus of the Murray group is to provide a better understanding of the molecular 
events leading to the development of Hodgkin’s lymphoma (HL) and especially of the role 
of the Epstein-Barr virus in this process. Although the tumour cells of HL have rearranged 
Ig genes, they do not express a functional B cell receptor (BCR), either because of crip-
pling mutations in their somatically mutated Ig genes or by the loss of transcription factors 
important for Ig-transcription. Thus, a fundamental pathogenic event in the development 
of HL is the ability of HRS cells to escape the apoptosis that would be the normal fate of 
GC B cells lacking functional BCR expression. We have recently shown that HRS cells are 
intrinsically resistant to Fas-induced cell death and that they express the Fas inhibitory protein, c-FLIP (Dutton A 
et al., Proceedings National Academy Sciences USA 2004). We have observed that down-regulation of c-FLIP, through 
the use of specific small interfering (si) RNAs, leads to HL cell death. Furthermore, we have also demonstrated that 
HRS cells express Fas ligand (FasL) and that treatment of HL cells with both c-FLIP- and FasL-specific siRNAs in 
combination restores cell viability. These results provide a mechanism whereby HRS cells appear to be protected from 
autonomous FasL-mediated cell death. Work is ongoing to determine whether FasL expressing HRS cells can evade 
immunosurveillance through a counterattack mechanism involving Fas-induced death of HRS-specific CTLs. Other 
work has identified the epigenetic silencing of key tumour suppressor genes with pro-apoptotic functions in HL cells 
(e.g. Murray et al., Oncogene 2003) which might be an important step allowing BCR-negative cells to survive in the 
GC. Clearly, EBV might provide important survival signals in GC B cells which might facilitate the escape of BCR-
negative progenitors- we are currently investigating the likely nature of these potential signals. More recent work is 
focused on a detailed analysis of the HL phenotype in vivo and how EBV infection contributes to this. Thus, we have 
recently shown that EBV confers growth and survival promoting effects upon HL cells via the transcriptional altera-
tion of key target genes, including autotaxin (Baumforth et al., Blood 2005).
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NFκB, Jak/STAT) that are also known to be deregulated 
in HL, it seems plausible it might also contribute to the 
HRS phenotype.
We have undertaken gene expression profiling follow-
ing EBV infection or gene transfection of transformed cell 
lines and of normal human GC B cells. This revealed tran-
scriptional changes consistent with those observed in cul-
tivated and primary HRS cells including the characteristic 
loss of B cell identity. These data not only implicate EBV 
as an important mediator of the HRS-cell phenotype, they 
also suggest that EBV infection of GC B cells modulates 
changes in gene expression that may play an important 
role in the early stages of the development of HL.
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HUMAN ENDOGENOUS RETROVIRUS HERV-K10 IMPLICATED IN RHEUMATOID 
ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS: 
POTENTIAL PATHOLOGICAL TRIGGERS?
Paul N Nelson, M Shaw, D Roden, G Freimanis, A Nevill, P Rylance
Research Institute in Healthcare Science, University of Wolverhampton, UK
Human endogenous retroviruses (HERVs) are a group 
of integrated RNA viruses within our human genome. 
Whilst many are regarded as defective, a number pos-
sess the potential to generate retroviral products. Indeed 
HERVs such as those belonging to the HERV-K family 
produce retroviral particles in the teratocarcinoma cell 
line GH and the breast cancer cell line T47D. It has been 
argued that some retroelements may be beneficial to the 
Paul N. NELSON, Dr., Associate Professor
Paul N Nelson is Reader/Associate Professor in Biomedical Sciences (Immunology) and 
a core member of the Research Institute in Healthcare Science at the University of Wolver-
hampton, U.K. His research group focuses on viral immunology, in particular the detection 
and role of human endogenous retroviruses (HERVs) in autoimmunity and cancer and the 
development and application of antibodies as probes and diagnostic/prognostic reagents 
in immunoassay systems. The immunology team consists of three senior lecturers, two re-
search assistants and ten PhD students plus additional visiting fellows. The reputation of 
the group has gained much acclaim from many publications, invitations to conferences and 
book chapters plus media presentations. More importantly, Dr. Nelson has worked closely with Professor Zdenek 
Kolar (University of Palacky) on the ERASMUS exchange link for several years that has brought much benefit to 
the training and research experience of postgraduate students. At the heart of his team’s ethos is the encouragement 
of all staff to reach their potential, to try novel ideas and expand the scientific knowledge of how viruses affect the 
immune system.
After gaining his degree in immunology and physiology at the University of London, Dr. Nelson was fortunate to 
work at the prestigious Royal Postgraduate Medical School, London, under Professor Mitchison and Dr. Ann Rees. 
The research focused on TB and provided an insight and a real interest into the world of microbes and disease. He was 
subsequently awarded a CASE PhD studentship in immunology and forensic science under Professor Roy Jefferis at 
the Medical School, University of Birmingham. It was at Birmingham that skills in antibody technology for clinical 
benefit were established. Indeed, one monoclonal antibody A57H (pan-IgG) was marketed and others (anti-allotypic 
reagents) have proved useful to this day for probing epitopes on immunoglobulin G. Much of Dr. Nelson’s postdoctoral 
experience was gained at St. George’s Hospital Medical School, London. Training in pathology was initially provided 
by Professor Tim Chambers whose interest was in bone diseases. Subsequently a major opportunity arose to work with 
Professor Frank Hay, Dr. Claire Sharrock and Professor Andrew Lever. Much is owed to these individuals for opening 
the way for research into RNA viruses and their role in autoimmune diseases. To this day, Dr. Nelson still works with 
Professor Hay and Professor Andrew Lever on HERVs, rheumatoid factors and, epitope mapping. His experience in 
virology was then expanded under the guidance of Dr. Jim Booth. Here Dr. Nelson led the team that provided a unique 
polymerase chain reaction test for cytomegalovirus in bone marrow transplant (BMP) patients. This test is still used 
routinely at St. George’s Hospital on all BMT patients and has no doubt saved many hundreds of lives. This probably 
serves as one of the best examples of ‘bench to bed’ medical research projects. Following a stint in cardiac immunol-
ogy and an appreciation of other viruses, an opportunity arose at the University of Wolverhampton to establish an 
immunology research group. The position was an act of faith and the risk was considerable since the university at that 
time had no immunology research or facilities to run postgraduate research programmes. Fortunately a like-minded 
colleague in the name of Dr. Paul Murray was already interested in DNA viruses, immunology and oncology. Right 
from the start an excellent working relationship began (and continues to this day) with many papers and research 
grants on HERVs, EBV and the link with the Czech Republic. From this beginning, new laboratories within RIHS were 
established with a thriving research community. Current projects include the development of monoclonal, polyclonal 
and phage antibodies to a number of HERVs including those implicated in breast cancer (Dr. Jan Martin) and brain 
tumours (Professor John Darling). In addition, various projects are investigating serological responses to HERVs in 
autoimmune diseases such as rheumatoid arthritis and system lupus erythematosus. In addition to research, Dr. Nel-
son is co-editor of the 3rd edition of the ‘biology of disease’ and will edit a book on HERVs in 2007. Fundamentally, 
he is also a teacher and trusts that his students all benefit in terms of knowledge from many years experience and his 
enthusiasm for immunology. To relax, Dr. Nelson enjoys skiing with his family and he flies aircraft.
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human host, perhaps conferring a selective advantage, 
whereas others may be harmful. Furthermore certain 
HERVs might be involved in the pathogenesis of autoim-
mune diseases. The precise mechanisms in diseases such 
as rheumatoid arthritis (RA) and systemic lupus ery-
thematosus (SLE) may include molecular mimicry and 
superantigen motifs that evoke and augment unwarranted 
immune responses. In the RA joint, tissue destruction is 
evident over time with recruitment of lymphoid and other 
cells plus the presence of rheumatoid factor that exhibits 
increased affinity and change in isotype; evidence of an 
antigen-driven immune response. The precise trigger of 
course, remains unknown although certain HERVs have 
been implicated. In a previous study we found evidence 
for increased expression of HERV-K10 mRNA in patients 
with RA. Here we have extended this work by investigating 
the serological expression to HERV-K10 in patients with 
RA, SLE, osteoarthritis, normals and other inflammatory 
disease groups. The study utilised a novel peptide ELISA 
immunoassay using segments of HERV-K10 identified 
through bioinformatic analysis. In particular, biotinylation 
of peptides was necessary for serological discrimination 
between patients. Overall a significant difference (p<0.05) 
was found for RA patients in terms of antibody activity to 
HERV-K10. There was also an increased level of antibod-
ies to HERV-K10 in patients with renal lupus although 
this was below the level of significance. It is possible that 
HERV-K10 could act as a trigger in RA/SLE through 
regions of similarity to host proteins. In this case, the 
immune response to HERV-K10 could lead to collateral 
damage and pathogenesis of disease.
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PURINE INHIBITORS OF CYCLIN-DEPENDENT KINASES AS NEW GENERATION 
OF ANTICANCER DRUGS
Miroslav Strnada, Libor Havlíčeka, Vladimír Kryštofa, Jan Hanuša, Lukáš Spíchala, 
Daniela Moravcováa, Jiří Moraveca, Marek Zatloukala, Igor Popaa, Martina Paprskářováa, 
Martin Orsága, Michal Otyepkab, Marian Hajdúchc, Petr Džubákc, Zdeněk Kolářd, 
Pavla Binarováe, Věra Cenklováe
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b Department of Physical Chemistry, Faculty of Sciences, Palacký University, tř. Svobody 26, 772 00 Olomouc, 
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c Laboratory of Experimental Medicine, Faculty of Medicine, Palacký University, Puškinova 6, 775 20 Olomouc, 
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Our research focused on the primary mechanism of ac-
tion of plant hormones cytokinins (N6-substituted adenine 
derivatives; 6-benzylaminopurine – BAP as representa-
tive) in cell division cycle has showed that natural plant 
cytokinins are rather non-specific inhibitors of various 
protein kinases1. Surprisingly, among aromatic cytokinin 
derivatives, we have discovered a compound, 2-(2-hydrox-
yethylamino)-6-benzylamino-9-methylpurine, named "olo-
moucine" (OC, Fig. 1), which specifically inhibits some 
cyclin-dependent kinases (CDKs) at micromolar con-
centrations [1]. The total lack of the inhibitory effect of 
olomoucine on major kinases, such as cAMP- and cGMP-
dependent kinases, protein kinase C, and others, suggests 
that OC might be a useful tool for cell cycle regulation 
studies. The design and inhibitory activity of OC was 
further improved by modifications at positions 2, 6, and 
9, i.e., the positions that control binding to CDK1. This 
led to discovery of novel specific CDK inhibitor named 
roscovitine, etc. (Fig. 1)2, 3, which displays enhanced in-
hibitory activity toward CDK1, a higher selectivity toward 
Miroslav STRNAD, prof. Ing., DSc.
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actively involved in the development of inhibitors of cyclin dependent kinases (olomoucin). 
He is author of 324 original articles (botany, biochemistry, physiology, analytical and organic 
chemistry), 12 chapters and reviews in textbooks, author of 3 books and 7 international 
patents. His citation index according SCI is more 1500 citations. He obtained the Award of 
European Fytochemical Society in 1998 for the analyses and identification of aminopurine 
fytohormones. Professor Strnad has also been an honorary member of Olomouc City since 
1999.
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Fig. 1. Chemical structures of 6-benzylaminopurine (BAP), olomoucine, roscovitine, olomoucine II, and purvalanol A 
(from left to right).
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some CDKs, an increased antimitotic activity at the G1/
S and G2/M points of the cell cycle, and stronger and 
more selective antitumour effects. Finally, we have tested 
different CDK inhibito rs on several tumour cell lines 
(CTLL-2, rhabdomyosarcoma cell lines, etc.). The average 
concentration that causes 50% growth inhibition range 
between 0.1–100 μM. The compounds are also effective 
in vivo and one is already in clinical trials (roscovitine ⇒ 
Seliciclib®, Cyclacel Ltd, U.K.). We have developed sev-
eral new generations of CDK inhibitors derived from the 
trisubstituted purines4–14. The purine analogues bohemine 
and roscovitine were also used to study the role on CDKs 
in cell cycle progression and microtubule organisation in 
Vicia faba root tip cells15. Both drugs inhibited the activity 
of immunopurified Vicia faba and alfalfa CDC2-kinase. 
An observed transient arrest at the G1/S and G2/M regu-
latory points indicated that inhibition of the CDC2-ki-
nase had an effect on both transitions. In contrast to the 
regular bipolar spindle in untreated cells, in drug treated 
metaphase cells abnormally short and dense kinetochore 
microtubule fibres were observed. The chromosomes were 
not aligned on the metaphase plate but were arranged in 
a circle, with kinetochores pointing inwards and chromo-
some arms pointing outwards. γ-Tubulin, which plays a 
role in microtubule nucleation, also localised to the centre 
on the monopolar spindle. These compounds also induce 
apoptosis in different cells in vitro and in vivo. We also 
recently discovered that compounds known as anticytoki-
nins are rather specific CDK inhibitors16. The results of re-
cent development will be presented during the meeting.
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BACKGROUND
Angiogenesis is considered a potential prognostic 
factor in chronic lymphocytic leukemia (CLL). Elevated 
levels of various angiogenic factors have been identified in 
plasma and serum of CLL patients. However, it is still con-
troversial whether neovascularisation in CLL bone mar-
row (expressed as microvessel density – MVD) is elevated, 
in part because methods of angiogenesis assessment are 
not directly comparable between studies published so far 
due to different antibodies used for immunohistochemi-
cal identification of vessels and different methods of cal-
culating MVD. Moreover, there are insufficient data on 
the association of bone marrow angiogenesis with type 
of marrow infiltration (focal/nodal, interstitial, diffuse) 
which have prognostic impact on the clinical course.
AIM
To assess MVD in marrow biopsies from CLL patients 
and a control group and to compare MVD according to 
infiltration type,
METHODS
We analyzed 22 CLL bone marrow biopsy specimens. 
The control group consisted of 11 biopsies from individu-
als with no evidence of bone marrow malignancy. Neo-
vascularisation was assessed using immunohistochemical 
staining of endothelial cells with anti fVIII Ag (von Wil-
lebrand-related antigen, factor VIII) monoclonal antibody. 
Microvessel density was assessed in digitalized pictures 
from Lucia-M image analysis software and calculated us-
ing the hot spot method, i.e. identification of three loci 
with highest accumulation of microvessels under low 
(100x) magnification and counting microvessels in three 
high-power fields (x400 magnification) per hot spot. MVD 
was expressed as number of microvessels per high-power 
field and per square micrometer.
RESULTS
Twenty-two CLL samples and 11 control specimens 
were technically evaluable. Type of infiltration was fo-
cal/nodular in 6, interstitial in 5 and diffuse in 11 sam-
ples. MVD was significantly elevated in the CLL group 
compared to controls (p < 0.0001, Mann-Whitney U test). 
On the other hand, we found no significant difference 
between CLL subgroups.
CONCLUSION
Our study shows that microvessel density in CLL is 
highly statistically significantly elevated over controls. 
However, we found no significant difference between fo-
cal vs. interstitial vs. diffuse type. In conclusion, this study 
adds further support to the importance of angiogenesis in 
CLL biology. Further studies assessing the association of 
MVD with other prognostic factors (e.g. IgVH mutation 
status, genetic aberrations) are necessary.
ACKNOWLEDGEMENT
Supported by grant No. NR/8373-3 and research project 
MZO 00179906 from Ministry of Health of the Czech 
Republic.
A2 MICROARRAY ANALYSIS OF GENE 
EXPRESSION IN MICRODISSECTED 
MAMMARY NORMAL AND TUMOR 
CELLS
Jan Bouchala, Gulisa Turashvilia, 
Karl Baumforthb, Wenbin Weib, 
Marta Dziechciarkovác, Zdeněk Kolářa
a  Laboratory of Molecular Pathology, Institute of 
Pathology, Palacký University, Olomouc, Czech Republic
b  Institute of Cancer Studies, University of Birmingham, 
UK
c  Laboratory of Experimental Medicine, Palacký 
University, Olomouc, Czech Republic
e-mail: bouchal@tunw.upol.cz
ABSTRACTS
34 
Key words: Wnt pathway/Cell adhesion/Ductal and 
lobularcarcinoma/Breast cancer/Microdissection/
Microarray
AIM
Breast cancer is a complex genetic disease character-
ized by the accumulation of multiple molecular altera-
tions. The resulting clinical heterogeneity makes current 
diagnostic and therapeutic strategies unsuited to individ-
ual patient needs. Breast cancer is extensively studied by 
many methods, including microarrays. The aim of this 
study was to contribute to the understanding of breast 
cancer by the microarray analysis of microdissected nor-
mal and cancer cells of both ductal and lobular type.
PATIENTS AND METHODS
We examined surgical specimens obtained by mastec-
tomy from 10 postmenopausal breast cancer patients. Of 
these 5 were invasive ductal, and 5 were lobular carci-
nomas. All tumors were negative for c-erbB-2 by immu-
nohistochemistry. Tumor tissue and normal mammary 
gland tissues were snap-frozen in liquid nitrogen. 7–8 μm 
frozen sections were stained by hematoxylin in RNase-free 
conditions. Normal lobular and ductal cells as well as 
infiltrating ductal and lobular tumor cells were microdis-
sected from cryosections using VeritasTM Laser Capture 
Microdissection System. Fifty nanograms of total RNA 
were amplified by combined PCR and in vitro transcrip-
tion. RNA was labelled during in vitro transcription and 
analysed on Affymetrix Human Genome U133 Plus 2.0 
Arrays. Gene expression analysis was performed by Affy-
metrix Gene Chip Operating Software, dChip software 
and Internet databases.
RESULTS
The genes overexpressed by tumor tissue were involved 
primarily in cell-matrix interactions, nucleic acid, zinc ion, 
ATP and protein binding (FN1, MMP2, CSPG2, POSTN, 
ASPN, BGN, MXRA5, AEBP1, LRRC15, SULF2). The 
expression of several genes was decreased in tumor tis-
sue: structural constituents of cytoskeleton (keratins 5, 
14, 15, 17, 23), genes with transcription factor and regu-
lator activity (ELF5, ID4, BHLHB3, TRIM29, FOSB), 
with protein serine/threonine and thyrosine kinase activ-
ity (ANXA1), with cytokine and growth factor activity 
(PTN, CX3CL1), genes involved in calcium regulation 
pathway (SFN, CAB39L, EGFR, DST, MGP), Wnt sign-
aling pathway (SFRP1), cell differentiation and apoptosis 
(CLU, GPM6B, NDRG2), purine metabolism (AK5), cell 
adhesion (CAV2), also oxytocin receptor gene (OXTR).
Genes, differently expressed in lobular carcinoma 
and normal lobular cells, are involved in cell adhesion 
(E-cadherin), electron (TSTA3, LOC203427) and pro-
tein (VTI1B) transport, N-Glycan biosynthesis (DDOST), 
calcium ion binding (DEF6), ERBB2 signaling (IL6R), 
negative regulation of transcription (COBRA1), zinc ion 
(ARFGAP1), GTP and DNA binding (SPG3A), ubiquitin 
activity (USP53). Genes, differently expressed in ductal 
carcinoma and normal ductal cells, are involved in zinc 
ion and DNA binding (PCGF4, EGR1, RAB18), cell cycle 
and cell-cell adhesion (DLG5), apoptosis (SULF1), Wnt 
signaling pathway (TCF7L2), protein and heparin binding 
(TXNL2, CD59, LAMC2), transcription (ELF3).
CONCLUSION
One of the major differences between breast cancer 
and normal breast epithelium lies in the expression of 
genes involved in Wnt/Ca2+ signaling pathway. This path-
way is important for both cell-cell and cell-matrix interac-
tions and affects invasion and metastasis of cancer cells. 
Wnt signaling molecules may represent potential targets 
for cancer therapy.
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AIM
Overexpression of cyclin D1 as a result of the chromo-
somal translocation t(11;14) is a highly specific marker for 
the diagnosis of mantle cell lymphoma (MCL). The aim 
of this study was to design a useful tool to quantify cyclin 
D1 transcript in fresh, frozen, formalin-fixed, paraffin-
embedded tissue sections and bone marrow specimens. 
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A second aim was to develop a precise and reliable ap-
proach for distinguishing MCL from other non-Hodgkin’s 
lymphomas (B-NHL).
MATERIAL/METHODS
We studied 107 primary tumours from patients diag-
nosed with a variety of B-NHL. These included 60 patients 
with MCL and 47 cases of other B-NHL, of which 26 had 
mucosa associated lymphoid tissue (MALT) lymphoma. 
In 36 specimens of MCL and 15 specimens of MALT 
lymphoma only formalin-fixed, paraffin-embedded tissue 
was available. In all remaining patients frozen tissue was 
analysed while lymph node tissue of five patients with a 
reactive lymphadenopathy was used as a control. In ad-
dition, we examined 100 bone marrow (BM) specimens. 
These consisted of 27 BMs with no MCL infiltration, 26 
BMs with MCL infiltration, 25 BMs with no infiltration 
by other B-NHL, 19 BMs with infiltration by B-NHL other 
than MCL and 3 BMs from healthy individuals.
We used real-time quantitative reverse transcription-
polymerase chain reaction (RQ RT-PCR) to quantify lev-
els of cyclin D1 mRNA. The assay involved RT-PCR with 
product detection using TaqMan technology. RQ RT-PCR 
is a specific, sensitive and effective method of molecular 
analysis which permits monitoring the level of analyzed 
molecules.
RESULTS
The range of cyclin D1 expression in patients with 
MCLs exceeded the range found in other lymphomas and 
reactive lymph nodes by a considerable margin. Overall, 
the overexpression of cyclin D1 was detected in 58 of 60 
MCLs. Increased levels of cyclin D1 mRNA was observed 
in several extranodal tissues of MALT lymphoma. This 
phenomenon can be explained by an admixture of non-ne-
oplastic epithelial cells present in the specimens because 
epithelial tissues are known to express cyclin D1. All other 
lymphoproliferative diseases and reactive lymph nodes 
were found to have low or no cyclin D1 expression and 
were easily distinguishable from cyclin D1 overexpress-
ing MCLs. There were no differences when expression 
levels in frozen tissues and formalin-fixed, paraffin-embed-
ded material were compared. Measurement of cyclin D1 
mRNA in BM specimens allowed us to differentiate BM 
from MCL infiltration and all other types of BM samples. 
All differences were statistically significant.
CONCLUSION
We were able to distinguish MCL from other B-NHL 
using this rapid, simple, and highly reproducible real-time 
PCR assay which is applicable to both routine archival 
material and bone marrow aspirates. Overall, the differ-
ence in cyclin D1 expression between MCLs and extran-
odal MALT lymphomas was statistically significant but 
the levels of expression overlapped to some extent. We 
therefore recommend correlating the level of cyclin D1 
mRNA with morphological, immunohistochemical and 
cytogenetical profiles in cases in which only extranodal 
tissues are available.
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AIM
To assess histopathological findings in surgical speci-
mens following uterine artery embolization.
MATERIAL AND METHODS
Between 2000 and 2005, 91 women were treated by 
uterine artery embolization because of symptomatic leio-
myomas and prospectively followed at our institution. 
Twenty subsequently underwent surgery. One patient 
underwent four surgical procedures. Embolic material 
used was tris acryl gelatine microspheres (TGMS) in 15 
patients (18 surgical specimens), polyvinyl alcohol parti-
cles (PVA) in three cases and a combination of both PVA 
and TGMS in another two cases. Twenty-three post-UAE 
specimens from 20 patients were evaluated. The material 
was routinely processed and sections from formalin-fixed 
paraffin-embedded tissue block were stained by hematoxy-
lin-eosin. In addition selected sections in each case with 
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identifiable particles were stained with Elastica van Gie-
son and examined immunohistochemically with antibody 
directed against CD31 antigen
RESULTS
Histologically, of the 23 examined specimens, 20 re-
vealed leiomyoma and 3 adenomyoma. Particles used for 
embolization were found in all but 3 specimens. Necrosis 
was present in 15/20 leiomyoma specimens. In 12 speci-
mens it was hyaline necrosis, in 1, coagulative necrosis 
and in another 2 cases it was a combination of hyaline and 
coagulative suppurative necrosis. The 3 adenomyomas 
remained unaltered.
CONCLUSION
The morphologic changes we found in post-UAE 
specimens were comparable regardless whether TGMS or 
PVA was used. We should be aware of the morphological 
changes associated with arteficial embolization of various 
types of particles to avoid the misdiagnosis leiomyosar-
coma especially in cases with coagulative necrosis, which 
can be accompanied by nuclear atypias and increased mi-
totic activity. In our study we failed to find any relation 
between extent of the regressive changes of leiomyomas 
and their size reduction. It is possible that other factors 
related to the host response to necrotic leiomyoma tissue 
play a role in the tumor size reduction.
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BACKGROUND
The Vitreoretinal interface and the Internal Limiting 
Membrane (ILM) of the retina is a recent subject of con-
centrated interest in the pathogenesis and surgical treat-
ment of diabetic macular edema (DME) and idiopathic 
macular hole (IMH) based on removal of the posterior 
hyaloid and ILM during microsurgery for. Complete re-
lease of traction forces and inhibition of reproliferation 
of fibrous astrocytes seem to be prudent in eyes with 
tractional maculopathy. Removal of the ILM leads to 
expedited resolution of DME, closure of the IMH and 
improvement in visual acuity.
Morphological identification of the peeled material as 
ILM and subsequent morphometry evaluation provides 
useful information about the role of ILM in the patho-
genesis of these diseases.
MATERIAL AND METHODS
Ultrastructure of the peeled ILM from patients that 
underwent vitreoretinal surgery was analyzed using fol-
lowing protocol:
1) 2.5% glutaraldehyde fixed surgically peeled ILM was 
embedded into arteficial resin (Durcupan-Epon)
2) Semithin sections were stained with toluidine blue and 
ILM identified
3) Ultrathin sections were contrasted with uranyl acetate 
and lead citrate
4) ILM was photographed with the electron microscope 
YEOL 1200 EX under the standard enlargement 
5000x with a 1 μm scale.
5) In the LUCIA G5 (Laboratory Universal Computer 
Image Analysis, Laboratory Imaging, Prague) the 
digitalized images were loaded, superimposed with 
a square grid of 500 px (= 3.25 μm). Any hit of the 
grid on a membrane was a place for the transversal 
ILM thickness measurement. The ILM of any patient 
with sufficient length of the membrane provided was 
measured on 10 photographs providing thus 40-50 di-
mensions for subsequent arithmetic mean + SD evalu-
ation
6) MS Excel predefined table served the final arithmetic 
mean + SD evaluation.
RESULTS
In 18 from 20 patients the material supplied for evalu-
ation was identified as ILM and measured. Mostly a sub-
stantial thickening of the ILM was found, especially in 
patients with DME (12 patients). It reached the thick-
ness 1.68 ± 0.43 μm to 4.69 ± 0.30 μm (a norm being 
0.5 μm).
Some cellular elements (mostly resembling macro-
phage) were observed on the vitreous side of the peeled 
ILM in both groups. The thickness of the peeled ILM in 
the DME group and the IMH group were significantly 
increased.
CONCLUSION
We conclude that ILM thickening and cell presence on 
the vitreous surface might contribute to the pathogenesis 
of the DME and IMH.
37Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150 (Supplement 1)
Ultrastructural morphometry of the ILM represents a 
tool for an objective vitreoretinal interface surgery evalua-
tion and with the qualitative evaluation and patients’ clini-
cal status monitoring it is the basis for further study of 
the pathogenetic mechanisms in the traction maculopathy 
diseases.
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Published studies on prostate carcinoma report a 
strong connection between the c-myc gene amplification 
and immunohistochemical overexpression of the Myc pro-
tein. It is assumed that excessive Myc protein expression 
causes degradation of protein p27 resulting in activation 
of the pathway of cyclin E/cyclin-dependent kinase 2 and 
cell proliferation.
Since it is known that numerous chromosomal and ge-
netic abnormalities are connected to prostate carcinoma 
progression, the aim of the study was to show whether any 
relation exists between protein p27 expression and various 
genetic abnormities. Given that in prostate carcinoma, 
chromosome 8 is most usually affected, deletions 8p22 
and amplifications of zone 8q24 being the most frequent 
chromosomal changes, these were the most appropriate 
ones for evaluation.
Our findings are in complete accord with the literature. 
Degradation of protein p27 represented by expression in 
0-25 % prevailed in a group of prostate cancers with a find-
ing of chromosomal changes. In carcinomas with ampli-
fication of the c-myc gene, the finding was a significantly 
reduced expression of protein p27 in 89.47 %.
Table 1. Expression p27, Gleason score, Deletions 8p22, 
Amplifications 8q24, Polysomia of 8 chromosome
p27 %
positiv 
nuclei
Gleason 
score
(group)
Deletions
8p22
Amplifications
8q24
Polysomia of
8 chromozom
15 2 no yes (AI) no
5 2 yes no no
0 2 yes no no
0 2 yes no no
25 3 yes yes yes
25 3 yes yes yes
5 2 yes no no
0 3 yes yes yes
25 2 yes yes yes
5 2 no yes yes
0 3 no no no
25 2 no no no
5 3 yes yes yes
50 3 yes yes yes
5 2 no yes yes
0 2 no yes (AI) no
0 2 no no no
25 2 yes no no
5 2 no no no
25 3 yes yes yes
0 2 yes yes yes
5 2 no no no
5 2 yes no no
5 2 yes no no
25 2 yes no no
5 2 no no no
0 1 yes yes no
0 1 no no no
25 3 yes yes yes
5 1 no yes yes
25 1 no no no
25 2 yes yes no
75 1 yes yes yes
0 2 no yes yes
0 2 yes yes yes
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AIM
Definition of the molecular basis of a fatal infantile 
most probably underdiagnosed complex neurovisceral 
lysosomal disorder and description of its phenotype at 
all essential levels.
MATERIAL AND METHODS
Three postmortem studied cases, cultured fibroblasts, 
white blood cells and urine studied histologically, confo-
cal microscopy, electron microscopy, enzyme and lipid 
biochemistry, lipid loading tests and molecular genetics.
RESULTS
The above disorder is defined by the absence of prosa-
posin (pSap) a multifunctional protein with trophic, main-
ly neurotrophic functions which is converted in lysosomes 
to four peptides (Saps), activating a set of six lysosomal 
sphingolipid hydrolases which are profoundly deficient 
even in wild type state. Absence of prosaposin is caused 
by mutation in its gene leading to either nuclear nonsense 
mediated decay (frame shifts) or interference with trans-
lation. At the lysosomal level the disorder is manifested 
in nonneuronal cells by absence of SAPs leading to defi-
ciency of about six sphingolipid hydrolases which leads 
in turn to extensive multiple lipid storage encompassing 
ceramide, galacto- and glucocerebroside, globotriaosyl-
ceramide, lactosylceramide, sulphatide. Neuropathologic 
study of three cases of prosaposin (pSap) deficiency, ages 
at death 27, 108 and 119 days, carried out in standard au-
topsy tissues revealed neurolysosomal pathology different 
from that in nonneuronal cells. The lysosomes in the cen-
tral and peripheral neurons were distended by pleiomor-
phic nonlipid aggregates which lacked specific staining 
and autofluorescence. Lipid storage was borderline on day 
27 and in low abundance at later stages. Neurolysosomal 
storage was associated with massive ubiquitination that 
was absent in nonneuronal storage cells. Confocal mi-
croscopy and cross-correlation function analysis revealed 
positive correlation with late endosomal/lysosomal mark-
ers. We hypothesise that the neuropathology reflects dis-
regulated influx of membrane components (either in bulk 
or as individual molecules) into neurolysosomes. Cortical 
neurons appear to be uniquely vulnerable to pSap defi-
ciency. Whereas on the day 27 they populated the cortex, 
on days 108 and 119 they were replaced by dense popula-
tions of both glial phagocytes and astrocytes. We suggest 
that massive neuronal destruction reflects a cortical crisis 
precipitated by the lack of pSap. The results of our study 
may extend knowledge of the neurotrophic function of 
pSap that should be considered essential for the survival 
and maintenance of human neurons.
CONCLUSION
The disorder is most probably underdiagnosed. To the 
date six cases, has been diagnosed in five families. Simple 
diagnostic tests are recommended.
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AIM
Diagnosis of an adult type of visceral lysosomal stor-
age disorder in a 53 year old female patient who died 
of acute pulmonary embolism without significant prior 
health problems. Autopsy disclosed hepatosplenomegaly, 
lymphadenopathy with storage histiocytes originally inter-
preted as Gaucher cells.
MATERIAL AND METHODS
Formaldehyde-fixed paraffin-embedded tissues were 
available for analyses. We used standard histology and 
histochemistry together with DNA analysis of relevant 
genes using DNA extracted from the autopsy samples and 
from peripheral leukocytes of family members.
RESULTS
Samples of the liver, spleen and some lyphnodes 
were infiltrated by variously dense storage ceroid-rich 
vacuolized histiocytes. Initial suspicion of Niemann-Pick 
disease type B were excluded by showing normal ASM ac-
tivity in obligate heterozygotes and by direct sequencing of 
the SMPD1 gene which revealed no pathogenic sequence 
variations. This raised suspicion of the NPC disease. No 
pathogenic sequence variations were found in the NPC2 
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gene. Two novel sequence variations c.1997G>A (S666N) 
and c.2882A>G (N961S) were detected in NPC1 gene not 
found in more than 300 control alleles. Final diagnosis: 
NPC1 disease.
CONCLUSION
The patient represents a third case of this extremely 
rare adult visceral variant of NPC1 disease (1,2) and it 
may be underdiagnosed.
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BACKGROUND AND AIM
Proteins of the STAT family are transcription factors. 
Through binding to DNA specific sites and consequent 
regulation of gene transcription, these signaling proteins 
play an important role in many cell functions. Recent 
studies have demonstrated persistent activation of STATs 
and loss of their natural inhibitors SOCS and PIAS in 
various human neoplasias including prostate cancer. It 
has been found that prostate carcinoma cells lines express-
ing persistently activated STATs become dependent on 
their transcription factor and that experimental inhibi-
tion of STAT signaling in these cell lines lead to massive 
apoptosis. Therefore, experimental pharmacological or 
genetic modulation of their function offers a promising 
new approach in anticancer treatment. Moreover, to date, 
it is not clear whether STATs signaling is related to the 
hormone responsiveness of prostate carcinoma. The aim 
of our study was to evaluate the STATs expression profile 
in prostate cell lines (DU-145, PC-3, LNCaP and C4-2) 
and determine any changes after treatment by the andro-
gen receptor antagonist, bicalutamide.
MATERIAL AND METHODS
The IC50 of bicalutamide was determined by the cell 
viability assay (MTT-test) and STAT1, phospo STAT1, 
STAT2, STAT3, phospo STAT3, STAT5 and phospo 
STAT6 expression was analysed by the Western blot 
technique.
RESULTS
Our results showed considerably lower expression of 
activated phospo STAT1, phospo STAT3 and phospo 
STAT6 in the hormone sensitive cell line LNCaP charac-
terised by higher p27 expression, wild type p53 and less 
aggressive growth in contrast to the hormone negative 
cell lines DU-145 and PC-3. Treatment with IC50 of bi-
calutamide (80μm) led to reduced expression of STAT1, 
phospo STAT1, STAT 2, STAT3, phospo STAT3, STAT5 
and phospo STAT6 expression in both hormone sensitive 
and in hormone negative cell lines.
CONCLUSION
These results clearly support the currently accepted 
theory that pharmacological reduction of STAT activity 
can lead to growth inhibition in prostatic cancer cell lines. 
We also demonstrated that STATs can be related to hor-
mone sensitivity. The exact mechanism of this relation-
ship however remains to be elucidated.
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AIM
It is widely accepted that malignant transformation is 
caused by accumulation of genetic mutations of somatic 
cells which permit autonomous growth and the uncon-
trolled cell proliferation associated with loss of cell-cycle 
regulation. However, the behaviour of tumors is also in-
fluenced by its microenvironment. It has been discovered 
th0at tumor cells can regulate development of specific 
tumor promoting stroma and stromal cells reciprocically 
affect the differentiation of malignant cells. Changes in 
extracellular matrix composition, increased protease activ-
ity, cytokines and diffusible growth factor production, the 
presence of inflammatory cells, fibroblasts and increased 
angiogenesis are important factors determining tumor 
growth and invasion. The purpose of the present study 
was to evaluate the changes in the microenvironment sur-
rounding malignant melanomas.
MATERIAL AND METHODS
Our study included superficial spreading (SSM) and 
nodular melanoma (NM) biopsies from 77 patients diag-
nosed at the Institute of Pathology between 2000–2005. 
As a control group, 43 benign pigment compound and 
intradermal nevi were examined. Immunohistochemical 
staining for VEGF-A, VEGF-C, PDEGF, bFGF, c-Myc 
and nestin were performed on formalin-fixed, paraffin-
embedded tissue sections. The results were statistically 
analyzed by Chi-square test (p < 0.05).
RESULTS
Malignant lesions revealed enhanced expression of 
the proteins immunohistochemical staining exhibited 
mostly in fibrocytes, endothelial cells and some inflamma-
tory cells, predominately macrophages and lymphocytes. 
Each protein was also detected in the neighbourhood 
of moles, but in lower levels. The differences between 
microenvironment immunoreactivity of these proteins 
in melanomas and benign nevi (VEGF C, p < 0.0001, 
PDEGF, p < 0.0001; bFGF p < 0.0001; c-myc, p < 0.0003; 
nestin, p=0.0001) were statistically significant except for 
VEGF-A.
CONCLUSIONS
Our study confirms that the investigated proteins have 
an impact on malignant stromal phenotype formation. 
Mild stromal changes were observed even in early staged 
melanomas but remarkable stimulation of stroma environ-
ment accompanied mainly advanced stages (Breslow III, 
IV, V). We conclude that stroma-tumor interaction can 
promote proliferation and dedifferetiation of malignant 
cells. These findings have important therapeutic implica-
tions.
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AIM
The aim of this work was to optimalise the cultivation 
of tumor and normal astroglial cells.
MATERIAL/METHODS
Tissue samples were taken from primary glioblastoma 
multiforme (grade IV) of a male aged 41 and from the 
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normal surrounding tissue from primary brain lymphoma 
of a female aged 61. Tissue samples were immediately 
homogenized and cultivated in medium DME F12 with 
10% of foetal bovine serum and with addition of growth 
factors: epidermal growth factor (EGF), insulin, hydrocor-
tisone and bovine pituitary extract (BPE). Cells derived 
from glioblastoma showed comparable level of growth in 
medium with and without growth factors. Cells isolated 
from nontumorous tissue needed growth factors for per-
manent cultivation . the first characterisation of isolated 
cells was achieved by immunocytochemistry and Western 
blot analysis using primary antibodies against: glial fibril-
lar acidic protein (GFAP), S 100 protein, vimentin, nestin, 
desmin, CD68 and PTEN. Antigens were visualised by 
fluorescent conjugates of secondary antibodies.
RESULTS
Cells isolated from glioblastoma showed higher growth 
than cells isolated from nontumorous tissue. Both types 
of cells were characterised by astroglial morphology with 
several long processes but tumorous cells were smaller 
and more elongated than nontumorous cells. After 60 
days of cultivation, nontumorous cells grew very slowly 
almost stopped growing and changed morphology. Cells 
lost the ability to adhere and they detached from the sur-
face. Nontumorous cells showed a limited lifetime prob-
ably determined by a limited number of cell divisions. Cell 
immortalization enables its cultivation. We aim to pre-
pare stable transfection clones with gene for telomerase 
in hTERTpClneo plasmid. Both types of cells expressed 
S 100 protein (typical for cells of neural origin), and vi-
mentin (marker of connective tissue and the precursor 
of GFAP in immature glial cells). The co-expression of 
vimentin and GFAP is described in mature astrocytes but 
never in ganglial cells. The absence of muscular marker – 
desmin and marker of phagocytic cells (oligodendrocytes 
in CNS) – CD68 exludes a muscular or oligodendroglial 
origin. The marker of stem cells – nestin was detected in 
nontumorous cells. In cells isolated from glioblastoma it 
was weakly positive, probably in connection with tumour 
dedifferentiation. GFAP is the main cytoskeletal protein 
of astrocytes in CNS and it was detected in the cytoplasm 
of tumor cells. No expression of GFAP in nontumorous 
cells was found. These results do not exlude less mature 
forms of astrocytes, where GFAP do not have to be pre-
sented. The expression of the tumor suppressor PTEN 
which is alterated in advanced stages of tumour progres-
sion was detected in both types of isolated cells.
CONCLUSION
Our results show the possibility of cultivating cells 
isolated from tumor and nontumor brain tissue. Estab-
lishment of stable nontumorous cell line is more difficult 
given the necessity of growth factors and immortalisa-
tion.
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INTRODUCTION
Polyomaviruses (BK and JC viruses named after the 
initials of the first patients with the disease ) are ubiqui-
tous infectious agents and around 90 % of adults in the 
general population have serological evidence of previous 
infection. Reactivation of BK virus infection can occur 
spontaneously or in individuals with a depressed immune 
response. BK-virus nephropathy (BKN) is also the most 
common viral disease in renal allografts. The disease out-
come in this case is often unfavorable with functional 
deterioration and high risk of graft failure. Interstitial 
inflammatory cell infiltrates may be reactions to the vi-
ral infection or they may indicate acute rejection. Precise 
diagnostic interpretation of inflammatory changes in the 
setting of BKN in renal cortex is difficult, especially if the 
pathologist considers the “interstitial type of rejection” 
(I A or I B according to the Banff classification).
METHODS AND RESULTS
BKN was identified in 6 patients in 12 biopsies and 2 
graft nephrectomy specimens of 1 115 biopsies between 
September 2000 and December 2003. The prevalence 
of BKN was 1.25 % in the graft biopsies. Definite virus 
identification was done by immunohistochemistry (mono-
clonal antibody α SV 40T, Oncogene, MA, USA; LSAB 
+ kit, DakoCytomation, Denmark). Simultaneously CD 
20, CD 45R0 and CD 68 positive cells in inflammatory 
infiltrate were detected by the immunoperoxidase dou-
ble immunostaining method (α SV 40T, Oncogene, MA, 
USA; Histofine Polymer detection system, Nichirei, Ja-
pan; DAB, DakoCytomation, Denmark and α CD 20, α 
CD 45 R0, α CD 68 DakoCytomation Denmark, LSAB 
42 
+ kit, DakoCytomation, Denmark; AEC, DakoCytoma-
tion, Denmark).
The inflammatory infiltrate was composed mainly of a 
subpopulation of CD 45R0 positive cells. CD 20 positive 
B cells represented no more than 10 %. CD 68 cells were 
identified in the lumina of tubuli and scattered as a part 
of the inflammatory infiltrate.
CONCLUSION
At present, BKN is the most common viral disease af-
fecting renal allografts with high risk of graft loss. Analy-
sis of the inflammatory cells in our study showed that CD 
45R0 positive cells represent the main subpopulation of 
lymphocytes without the morphological features of signifi-
cant tubulitis. Macrophages and B cells were observed in 
low numbers as a part of the cooperating inflammatory 
cells. There is no simple and sensitive marker for recogniz-
ing inflammatory cells as due to rejection or infection. In 
the future pathologists will need to identify such a marker 
for indicating whether inflammatory cells are the result of 
alloantigen-dependent or – independent stimulation.
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AIM AND BACKGROUND
Resistin is an adipocytokine with proposed relation to 
insulin resistance, diabetes and obesity. Recently, its an-
tiinflammatory properties have been suggested. The aims 
of the study were to evaluate the expression and localisa-
tion of resistin in synovial tissue samples from patients 
with rheumatoid arthritis (RA) and osteoarthritis (OA), 
to analyze serum and synovial fluid resistin levels and 
evaluate its association with inflammation and disease 
activity in RA patients.
MATERIAL AND METHODS
Synovial tissue was processed by routine paraffin tech-
nique and immunohistochemistry using a set of antibod-
ies against resistin, CD20, CD3, CD138 and CD68. The 
results were confirmed with laser-confocal microscopy. 
Serum and synovial fluid samples were withdrawn simul-
taneously. The concentration of resistin was analyzed 
by commercial ELISA kits. Systemic inflammation was 
determined using high sensitive (hs) C-reactive protein 
measured by ELISA. The clinical activity of RA patients 
was assessed according the 28 joint count Disease Activ-
ity Score (DAS28).
RESULTS
Resistin was expressed in the lining, and particularly in 
contrast to OA samples, in the sublining layer of synovial 
tissue. It was localised predominantly to inflammatory 
cells such as plasma cells, B lymphocytes and macro-
phages. Serum and synovial fluid resistin levels were sig-
nificantly higher in RA compared to OA patients (7.0 ± 
3.0 vs. 4.4 ± 1.6 ng/ml, p<0.001 and 37.5 ± 13.4 vs. 1.6 
± 0.8 ng/ml, p < 0.001, respectively). In RA patients, sig-
nificantly higher resistin levels were observed in synovial 
fluid than in serum. In contrast to synovial fluid, serum 
resistin correlated with both CRP (p < 0.02) and DAS28 
(p = 0.05) in RA patients. Resistin level did not corre-
late with leukocyte count in synovial fluid neither in RA 
(r = 0.17, p = 0.49) nor in OA patients (r = 0.17, p = 0.49).
CONCLUSION
Serum resistin may represent a new biomarker reflect-
ing systemic inflammation and clinical disease activity 
in patients with RA. Moreover, increased expression of 
resistin in RA synovium suggests resistin plays a role in 
the pathogenesis of RA.
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OBJECTIVE
To evaluate the indications, techniques, strategies, com-
plications and outcomes of the prostate biopsy performed 
in patients with suspected prostate cancer (PCa).
MATERIALS AND METHODS
Indications for prostate biopsy are either pathologi-
cal findings on digital rectal examination (DRE) or more 
recently high levels of prostate specific antigen (PSA) or 
rapid PSA increase,PSA velocity (PSAV). Sextant biopsy 
was the standard method for a long time. Currently, ac-
cording to the size of the prostate, a number of bioptic 
cores is taken (Vienna nomogram, multiplicated biopsy). 
Rebiopsy is indicated in cases of persistent suspicion of 
cancer after the first biopsy or unclear histological finding 
in the first biopsy. There are several clinically important 
and serious complications of prostate biopsy such as in-
fection and haemorrhage. However, these occur in at a 
very low rate (< 1 %). Cancer detection is completely 
dependent on the indication criteria the prostate biopsy. 
Most authors report < 25 % cases.
RESULTS
As a result of the programme of early detection of 
PCa in the Olomouc region, we are registering a rising 
number of prostate biopsies at the Department of Urol-
ogy, University Hospital in Olomouc. In 2003, there were 
approximately 350 biopsies, 720 in 2004 7, 1250 in 2005. 
We had less than 0.5 % complications. PCa detection was 
less than 25 %.
CONCLUSION
Prostate biopsy is a safe outpatient diagnostic method 
with minimal complications. From the viewpoint of a pa-
thologist, the quality of the material acquired is crucial 
to determination of the histological type of tumor and 
Gleason score. These data have fundamental significance 
not only for prostate cancer diagnosis but also for predict-
ing the course of the disease and treatment strategy.
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AIM
Cytochrome c oxidase (COX) deficiency represents 
a heterogenous group of disorders. In addition to the 
13 structural subunits of this mitochondrial enzyme, there 
are numerous proteins encoded by nuclear DNA which 
are required for efficient COX assembly and maintenance. 
A structural and histochemical study was carried out in 
a series of 7 cases (from 5 families) with isolated cyto-
chrome c oxidase deficiency caused by mutations in SCO2 
gene. This research correlated phenotype at the clinical, 
histological, biochemical and histochemical levels with 
genotype.
MATERIAL AND METHODS
Paraffin-embedded, formaldehyde-fixed and frozen tis-
sues from autopsy and less frequently from biopsy were 
studied using light microscopy, respiratory enzymes his-
tochemistry, immunohistochemistry and electron micro-
scopy.
RESULTS
The morphological study disclosed changes concen-
trated in the nervous system, skeletal muscle and myocar-
dium in SCO2 dependent manner. Neurodegeneration 
and neuronal drop out were seen in the central nervous 
system in all cases. There is evidence that retinal neu-
rons may be seriously affected, too. No typical necrotic 
lesions in the basal ganglia associated with Leigh syn-
drome were found. Involvement of motoneurons and 
peripheral nerves together with cytochrome c oxidase 
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deficiency in muscle tissues represent ,,double hit” for 
the skeletal muscle. There were 2 distinct phenotypes 
in the examined cohort of patients. In 5 patients with 
dominant neuromuscular phenotype the average life span 
was 9–12 months. All these children were homozygous 
for the missense mutation 1541G > A in the SCO2 gene 
(E140K). The mitochondrial population was not found 
to be significantly increased or structurally altered. In 2 
other cases, the course of disease was more rapid (death 
at 7 and 11 weeks of life) and featured by early onset 
progressive cardiac hypertrophy (3- and 4- fold increase 
in heart weight). One patient was compound heterozygote 
for mutation 1541G>A and mutation 1280C>T, resulting 
in a premature stop codon (Q53X). The remaining patient 
had mutation 1541G>A and deletion 1518delA resulting 
in a frame shift and giving rise to a truncated protein. 
Cardiocytes displayed signs of hypertrophy and their 
mitochondria displayed both abnormal enlargement and 
alteration of the inner membrane. Similar mitochondrial 
alteration was identified in neurons of the retina available 
for study in onees in one. Biochemical and histochemical 
levels of COX in tissues corresponded with rapidity of 
clinical course.
CONCLUSION
In terms of pathology the overt structural phenotype 
of COX deficiency due to mutations in SCO2 gene in 
the studied cohort of patients can be characterized as 
neuromuscular degeneration with two subvariants differ-
ing in the degree of cardiac involvement. These variants 
correlate with two main genotypes described.
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AIM
Effective chemotherapy inducing regular apoptosis in 
Hodgkin lymphoma is linked with the proper function 
of apoptotic pathways, particularly of apoptotic effec-
tor caspase 3. Caspase 3 is activated through either the 
stress-induced pathway or the death receptor-mediated 
pathway. In some cases of classical Hodgkin lymhoma 
(cHL) the resistence to chemotherapy may be caused ei-
ther by ineffective activation of apoptosis or by inhibition 
of apoptotic execution. High numbers of active caspase 
3 positive neoplastic cells may reflect a regular activation 
of apoptosis and this phenomenon may result in favour-
able response to chemotherapy and in a better overall 
clinical outcome. The aim of the study was to investigate 
the correlation between active caspase 3 expression and 
response to therapy.
MATERIAL AND METHODS
We examined samples of primary cHL of 58 paediat-
ric patients diagnosed from 2000–2005. All cases were 
reevaluated and the diagnosis of cHL was confirmed by 
morphology and immunohistochemistry (CD30, CD15) 
in all cases. Formalin-fixed paraffin-embedded tissues were 
examined immunohistochemically using a primary anti-
body against the active caspase 3.
RESULTS
The results revealed positivity in 0 % to 13.5 % of the 
neoplastic Hodgkin and Reed-Sternberg (H/RS) cells. In 
accordance with other investigators, the cut-off level to 
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report a patient as caspase 3 positive, was set at 5 % of 
positive H/RS cells. In the investigated group of patients 
17 of 58 (29.3 %) were evaluated as positive. None of the 
17 patients relapsed or died in contrast to 6 patients who 
had a disease relapse (14.6 %) and with 1 patient who 
died in the group with a low number of positive neoplastic 
cells.
CONCLUSION
Immunohistochemical identification of chemotherapy 
sensitive cases of cHL may bring a valuable benefit in 
a pretreatment stratification of patients with Hodgkin 
lymphoma and in selecting targeted chemotherapy and 
radiotherapy.
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AIM
Synovial sarcomas (SS) are a rare soft-tissue tumor that 
effect children and young adults. SS are high-grade soft 
tissue neoplasms often characterized by a biphasic spindle 
and epitheloid morphology. The majority of synovial 
sarcomas harbor a specific chromosomal translocation 
t(X;18)(p11.2;q11.2), which results in a fusion of the 
SYT gene on chromosome 18 and with SSX genes on 
chromosome X. Despite advances in the treatment of local 
disease, distant metastases remain a dominant cause of 
death. Therefore, there is a need for alternative therapies, 
targeting receptor tyrosine kinases –ERBB-2 and against 
cell cycle regulators- for example BCL-2.
MATERIAL AND METHODS
Archival specimens of synovial sarcomas (n=25) 
were assessed for BCL-2 and ERBB-2 protein expression 
by standard immunohistochemical techniques (IHC). 
To validate the results of IHC, real-time quantitative 
reverse transcriptase plymerase chain reaction (RQ-RT-
PCR) assays using fresh and/or paraffin sections were 
performed. The results of IHC were assessed as diffuse 
and strong positivity (D3+), diffuse and moderate (D2+), 
diffuse and weak (D1+) and focal positivity (F1+ – 2+).
RESULTS
BCL-2 protein was detected by immunohistochemistry 
in 18/18 (100 %) – 3 cases with F1-D1, 10 cases with D2+ 
and 5 with D3+ positivity. ERBB-2 protein was detected in 
9/18 (50 %) synovial specimens but with only weak focal 
positivity. Coexpression of BCL-2 and ERBB-2 molecules 
was observed in 9/18 (50 %) synovial sarcomas. We ob-
served a mirror pattern in immunoreactivity of BCL-2 in 
biphasic synovial sarcomas. The positivity of epitheloid 
cells and negativity or a very weak positivity of spindle 
cells was detected in 4 cases, although in one, positivity of 
spindle cells with negative epitheloid cells was observed. 
RQ-RT-PCR demonstrated a massive content of mRNA 
for BCL-2 in 14/25 (56 %) cases, moderate in 28 % of 
BCL-2 and a weak in 16 % of synovial sarcoma speci-
mens. The presence of mRNA for ERBB2 was detected 
in 16/24 (67 %) cases in contrast to the results of immu-
nohistochemical techniques. 50 % patients with synovial 
sarcomas had a strong expression of ERBB2 proven by 
RQ-RT-PCR. We failed to observe any co-relation between 
the expression of ERBB2, BCL-2 and histotype or fusion 
gene SYT/SSX1 or SYT/SSX2.
CONCLUSION
BCL-2 and ERBB2 are expressed in a high percentage 
of synovial sarcomas. Treatment with antisense BCL-2 
may be an appropriate alternative therapy for these pa-
tients. The treatment with tyrosine kinase inhibitors in 
connection with expression of ERBB2 is debatable given 
the low expression of the ERBB-2 protein.
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In 1956, Symmers et al reported that the gastrointes-
tinal tract was involved in 70 % of primary amyloidosis 
but he did not mention how frequently those patients suf-
fered from cardiomyopathy. Since then the topic has been 
almost forgotten and the recent restrictions on autopsies 
in Britain have contributed to limitating further research 
in this field.
Cardiac amyloid is occasionally considered in patients 
with restrictive cardiomyopathy diagnosed on echocar-
diography but definitive diagnosis requires myocardial 
biopsy.
Our data comprise material from 12 cases of general-
ised amyloidosis collected over 10 years in the south of 
England. The majority was sudden death and the age var-
ied from 74–97 years. The clinical information available 
was usually almost nil. The autopsy and the histochemical 
results showed typical myocardial changes together with 
the amyloid in the submucosal arterioles and veins of the 
digestive tract, particularly the stomach, also in the other 
organs except for the glomeruli.
The results show that the joint involvement of the 
blood vessels of the heart and the gut in senile amyloido-
sis is so common that in cases of cardiomyopathy it would 
be worth considering the biopsy of stomach rather than 
that of the myocardium, if amyloidosis is suspected, as 
the risk of complications is smaller with biopsy of the 
stomach.
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OBJECTIVE OF THE STUDY
The aim of the study was to determine how Q Dot 
conjugates prolong lifetime periods of positivity on sec-
tions where A- amyloid, IgG, IgA, IgM, C3, C1q comple-
ment, kappa and lambda light chains have been detected 
as detection of these proteins is used in the diagnosis of 
renal diseases. We identified these proteins using the one 
or two-step immunofluorescence detection method. The 
Q dot primary conjugate has been used for a detection of 
fluorescein conjugate antibodies for long – term observa-
tion of positive results.
MATERIAL AND METHODS
Tissues: 8 μm thick frozen sections were used for de-
tection of A- amyloid, IgG, IgA, IgM, C3, C1q comple-
ment, kappa and lambda light chains. Sections were put 
on slides coated with gelatine and air dried. Detection of 
proteins: IgG, IgA, IgM, C3, (Sevapharma, Prague) C1q, 
κ and λ light chains (DakoCytomation, Denmark), were 
detected by polyclonal antibodies directly conjugated by 
FITC. Detection of A-Amyloid was made using two-step 
indirect immunofluorescence technique (monoclonal 
antibody, DakoCytomation; SwAM-FITC, Sevapharma). 
Using of Q Dot: We used Q Dot 655 Goat anti Fluores-
cein Conjugate for detection of antibodies conjugated by 
fluorescein.
RESULTS
Observation of detected proteins: Observation of 
proteins was possible in two ways. Either in fluorescence 
spectroscopy microscope with filter excitation 460–
490 nm (FITC – green colour) or with filter excitation 
510–550 nm (Q Dot – red colour).
Long-term evaluation: A sequence of pictures was pre-
pared using both filters during 6 month. The evaluation 
revealed the long-term life of Q Dot detected proteins and 
on the other hand, as has been described and observed be-
fore, the short long-term life of FITC detected proteins.
CONCLUSIONS
Use of Q dot is useful for the study of proteins when 
there is a need for long time observation, especially when 
more than one pathologist evaluates it. It is also possible 
to observe sections repeatedly over time without loss of 
positivity. It is useful for archiving slides and in the train-
ing of pathologists as well.
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Clinical, histopathological, immunohistochemical and 
genetic analysis of two osteoclastic giant cell tumors of 
the pancreas is presented. The neoplasms were composed 
of osteoclastic giant cells and pleomorphic cells. The tis-
sue-specific markers provided evidence of the mesenchy-
mal nature of the osteoclastic giant cells as well as other 
components of the tumor but lacked any signs of epithe-
lial differentiation in either patient. The 
non-epithelial nature of both components in the osteo-
clastic giant cell tumors may be associated with a better 
prognosis and this corresponds to previous reports for 
similar neoplasms. A positive immunoreactivity to neu-
ron-specific enolase was recorded in patient 2.
The presence of CD68 in oteoclastic giant cells proved 
their histiocytic nature. Both components of the tumors 
showed a negative immunoreactivity to desmin and only 
a scattered reactivity to smooth muscle cell actin, typical 
markers of myofibroblastic differentiation.
Mutation analysis of the tumor revealed the wild state 
of both p53 and K-ras oncogenes in both patients. A pos-
itive immunoreactivity for p53 in pleomorphic cells of 
both osteoclastic giant cell tumors was recorded, while 
osteoclastic giant cells did not express this protein. The 
expression of p21 was recorded in osteoclastic giant cells 
in patient 1.
The absence of Ki–67 in the osteoclastic giant cells 
and its expression in pleomorphic cells gave evidence of 
a different proliferation rate in the two cell populations.
Different tissue – specific markers, a different prolif-
eration rate, and a different state of oncogene activation 
in the osteoclastric giant cell tumors contribute to the idea 
that the tumor derives from a pluripotent cell that may 
differentiate into an array of phenotypes.
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Histopathological analysis of 52 biopsies from 43 
critically ill adults, was focused on differential diagnosis 
and the course of illness in intensive care (poly)neuropathy 
(ICP) or myopathy (ICM). Needle or open biopsies were 
processed using a set of conventional histological and 
histo-chemical methods.
The results of electrophysiological examinations were 
unequivocal: 21 patients axonal polyneuropathy and 
6 axonal polyneuropathy with myopathy. The results of 
the histopathological examination of biopsies evaluated 
strictly according to the criteria applied to critically ill 
patients were different. Only 2 patients had unequivocal 
neurogenic atrophy. The majority of biopsies revealed a 
myopathic pattern, simple or necrotic myopathy.
The results of histopathological examination, where 
the presence of scattered, fascicular or diffuse fibre 
atrophy including angular myofibres are considered signs 
of possible myogenic as well as neurogenic lesion, brought 
about a marked shift towards this mixed neuromyopathic 
pattern and an increased proportion of concordant 
diagnoses of the IC neuromuscular disorders.
A follow-up study showed that ICM and ICP develop 
soon after disease onset. In 9 patients, the bioptical 
examination was repeated and the histological picture of 
the lesion changed in all cases. When the second biopsy 
was performed several months or years after the 1st one, 
all myogenic features i.e. picture of simple or necrotizing 
myopathy disappeared and either recovery with normal 
histopathological findings or a picture of a persistent 
neurogenic lesion was found.
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AIM
The Gleason system, the most widely used approach 
for grading prostate carcinoma, is based on evaluation 
of the microscopic structure (glandular pattern) of the 
tumour under relatively low magnification. One advantage 
of the Gleason system is that not only the highest grade of 
the tumour is evaluated. The system introduces a Gleason 
score, the total of primary (predominant) and the second-
ary (second most prevalent) architectural patterns that are 
identified and assigned a grade from 1 to 5, with 1 being 
the most differentiated and 5 being undifferentiated. The 
original Gleason system created 40 years ago has been 
refined and modified. The last modification was published 
in 2005 (Am.J.Surg.Pathol., 2005,29/9:1228). Within the 
last three years, we have collected and extensively exam-
ined a unique set of prostate carcinomas and in this pres-
entation we summarize our experience in Gleason grading 
in this set of carcinomas. We also introduce the recent 
modification to the Gleason grading system.
MATERIAL AND METHODS
Tumour specimens from 189 patients who had carci-
noma of the prostate were assessed. All patients under-
went radical prostatectomy at the Clinical Department 
of Urology, 3rd Faculty of Medicine, Charles University 
in Prague and Teaching Hospital Kralovské Vinohrady, 
Prague, Czech Republic. In all cases, native prostate was 
transmitted directly from the operating theatre to the 
Department of Pathology for biopsy examination. After 
macroscopic description, gross dissection of the whole 
prostate was performed in accordance with the scheme 
published in 1994 (Am.J.Clin.Pathol.1994,102:572). Tis-
sue blocks were then fixed with 10 % buffered formalin 
and embedded in paraffin for following the histological 
procedure. A Gleason score was assigned for histological 
slides stained with haematoxylin and eosin, independently 
by two pathologists (V.E., V.M.). The results were conse-
quently compared and consensually unified.
RESULTS
The tumours were obtained from 189 patients, rang-
ing in age from 50 to 79 years, mean 63 years. Tumours 
obtained from 113 patients were limited only to prostatic 
tissue (pT2), while tumours from 76 patients displayed 
extraprostatic extension into the periprostatic soft tis-
sue (pT3). In the group of pT2 tumours we classified a 
Gleason score of 3 in 4 patients (4x 2+1), a score 4 in 25 
patients (1x 1+3, 24x 2+2), a score 5 in 57 patients (41x 
2+3, 16x 3+2), a score 6 in 15 patients (5x 2+4, 8x 3+3, 
2x 4+2), a score 7 in 11 patients (10x 3+4, 1x 4+3) and 
a score 8 in one patient (1x 3+5). In the group of pT3 
tumours we classified Gleason score 3 in one patient (1x 
2+1), score 4 in 2 patients (2x 2+2), score 5 in 30 patients 
(14x 2+3, 16x 3+2), score 6 in 15 patients (10x 3+3, 5x 
2+4), score 7 in 13 patients (9x 3+4, 4x 4+3), score 8 in 
11 patients (5x 3+5, 3x 5+3, 3x 4+4) and score 9 in 4 
patients (2x 4+5, 2x 5+4).
CONCLUSION
Our experience in the evaluation of the Gleason score 
for grading of prostatic carcinoma is in agreement with 
the data published in recent years. A Gleason score of 2 is 
in general classified very exceptionally. In our set, no car-
cinoma of this score was identified. The majority of carci-
nomas are moderately differentiated (Gleason score 5,6) 
and in our set, 62 % of tumours belonged to this group. 
Well-differentiated carcinomas (Gleason score 3,4) were 
relatively more frequent in the group of pT2 tumours, 
while poorly differentiated carcinomas (Gleason score 
7,8,9) were found more frequently in the group of pT3 tu-
mours. A Gleason score of 10 was not classified in any of 
tumours of our set. The last modification of the Gleason 
system for grading prostate carcinoma introduced in 2005 
defines clearly the criteria for evaluation of the patterns 
characteristic for individual grades of tumour differentia-
tion. Exact application of the rules accepted for prostate 
carcinoma grading in this modified scheme is important 
in diagnostic practice, to assign an appropriate score for 
particular tumours and to reduce the differences between 
the pathologists doing the evaluation of tumour grade.
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IMMUNOHISTOCHEMISTRY OF 
ARTICULAR CARTILAGE AFTER 
AUTOLOGOUS CHONDROCYTE 
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AIM
Spontaneous healing of focal lesions in cases of adult 
articular cartilage is very limited. There are two basic ap-
proaches to cartilage tissue engineering that have been 
proposed: Implantation of cell alone or in combination as 
a cell seeded scaffold to promote regeneration in vivo. The 
objective was to evaluate the healing of cartilage defects 
implanted with autologous chondrocyte –seeded onto an 
acid based scaffold (Hydrograft C) prepared in Italy
MATERIAL AND METHODS
10 patients with articular defects were implanted with 
Hydrograft C and second-look biopsies were analysed af-
ter removal from the joint 10 months following cell im-
plantation. All patients showed clinical improvement and 
the macroscopic appearance at arthroscopy was normal 
or nearly normal in all cases. Histological examination 
and immunohistochemical staining were performed on 
formalin-fixed paraffin-embedded tissue.
RESULTS
The majority of the new tissue filling the defects was 
fibrocartilage and hyaline cartilage. Chondrocytes of both 
components stained positively with antibody for S-100 
protein and all specimens also contained numerous al-
pha-smooth muscle actin(SMA)–positive chondrocytes 
predominating in fibrocartilage areas. In all samples were 
observed signs of reparation in the subchondral bone in-
cluding loss of portions of subchondral bone plate and 
fibrous deposition in the marrow regions below. In some 
cases the remains of the degradable scaffold material were 
observed in the cytoplasm of bone marrow macrophages 
and rarely also in chondrocytes.
CONCLUSION
These findings confirm that the autologous chondro-
cytes implantation is a safe and effective option for the 
treatment of articular cartilage defects. Moreover, our 
results indicate that actin-positive chondrocytes (myo-
chondrocytes) play important role during the healing 
of articular defects implanted with autologous chondro-
cyte.
A24 A CASE OF EXCESSIVE AUTOPHAGY 
WITH MULTIORGAN INVOLVEMENT 
AND LOW CLINICAL PENETRANCE. 
A NOVEL LYSOSOMAL DISORDER?
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Cardiomyopathy/Hepatopathy
AIM
Characterization of the lysosomal lesion in a female 
patient aged 74 with clinical history of ischemic heart dis-
ease with bilateral cardial hypertrophy, hypertension, AV 
block, chronic bronchitis, dyslipidemia (cured by Simvac-
ard 20 mg/day), corticoid dependent rheumatoid arthritis 
(Prednison 5 mg/day), dyspepsia and diabetes mellitus 
type II, without manifest skeletal myopathy.
MATERIAL AND METHODS
Formaldehyde-fixed autopsy samples sent for consulta-
tion were processed for histology and electronmicroscopy. 
Paraffin samples were examined using routine stains and 
by immunohistochemistry using conventional and confo-
cal microscopy.
RESULTS
A generalized lysosomal disorder with features of ex-
cessive autophagy was identified in the heart, liver, and 
gut smooth muscle cells. The lysosomal compartment 
(LAMP1, LAMP2 and Cathepisn D positive) displayed 
ubiquitination in cardiocytes and in smooth muscle cells. 
We speculate there was an increased lysosomal load 
caused by permanent autophagy of organelles as could 
be inferred from gradual shift of mitochondrial epitopes 
including subunit c of the mitochondrial ATP synthase 
into the lysosomal compartment.
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CONCLUSION
The case may belong to a novel category of autophag-
ic disorders with late-onset and multiorgan involvement 
(1, 2). Lysosomal membrane dysfunction due to LAMP2 
mutation (Dannon disease) was excluded due to normal 
LAMP2 expression. Whether the process reflects primary 
dysregulation of autophagocytosis or is induced by a pri-
mary defect of mitochondrial membranes (or of mem-
branes of other organelles) cannot be answered.
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AIM
Case report describing an interesting case of lym-
phoepithelial lesion of the lacrimal gland.
MATERIAL AND METHODS
Surgically removed heterotopic and supernumerary 
lacrimal gland of a 50 years aged woman was bioptically 
examined by classical staining followed by immunohisto-
chemical technques. Fluorescein in situ hybridisation was 
later also performed after excision and biopsy of a second 
lesion of the submandibular salivary gland.
RESULTS
Lymphoepithelial lesion was revealed in the excised 
lacrimal gland of the patient. Initial suspicion of MALT 
lymphoma was not confirmed at first by immunohisto-
chemical analysis. Fluorescein in situ hybridisation, per-
formed on the lacrimal gland specimen, later biopsy of 
submandibular salivary gland where the picture of MALT 
lymphoma was more apparent, revealed genetic changes 
characteristic of MALT lymphoma in some cells within 
the lymphoid infiltrate of the lacrimal gland. The initially 
uncertain diagnosis of MALT lymphoma in the lacrimal 
gland was finally confirmed in this way. No signs of local 
recurrence, nodal involvement or systemic disease were ob-
served in this patient after a more than 1 year follow up.
CONCLUSION
Lacrimal gland is a rare but possible primary site of 
MALT lymphoma which may affect simultaneously or 
subsequently the salivary glands. Molecular pathology 
may become important and helpful in the final diagnosis 
of cases with an uncertain or doubtful picture using clas-
sical and immunohistochemical staining.
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AIM
Vulvar squamous precancerous lesions are currently 
classified according to the vulvar intraepithelial neoplasia 
(VIN) concept proposed by the International Society for 
the Study of Vulvovaginal Disease (ISSVD) in 1986. The 
new modified terminology of VIN lesions was worked up 
and recommended for general use by the ISSVD Vulvar 
Oncology Subcommittee in 2004. According to this revi-
sion, the grading of VIN lesions should be abandoned. 
The VIN I category will no longer be used and VIN II and 
VIN III categories will merge. The term VIN will describe 
high grade squamous lesions only encompassing the VIN, 
usual type (former VIN II and VIN III) and the VIN, dif-
ferentiated type (former VIN III). The aim of our study 
is to review the VIN I cases in our registry, to assess the 
prevalence of HPV types in these lesions and to discuss 
their possible biological behaviour with emphasis on the 
justification that the VIN I category should be abandoned 
from the classification scheme.
MATERIALS AND METHODS
The total of 18 lesions from 16 patients were enrolled 
in our study and divided in 3 groups: A. VIN I, usual type 
(4 cases, 4 patients), B. transition pattern VIN I – VIN 
II, usual type (6 cases, 4 patients) and C. foci of VIN I 
appearance in the field of inflammatory vulvar disorders 
(lichen sclerosus, lichen simplex chronicus) (8 cases, 8 
patients). Each lesion was screened for the presence of 
HPV DNA by means of PCR with GP5+/6+ primers and 
reverse line blot assay was used for the detection of up 
to 37 different HPV types. The relevant medical history 
(presence of HPV associated high-grade VIN, all grades 
of CIN, carcinoma of the vulva, vagina and uterine cervix 
and immunological status) of all patients was analyzed.
RESULTS
The prevalence of HPV DNA in groups A and B was 
100 %. No HPV DNA was detected in lesions classified 
under group C. Only high risk HPV types (16, 18, 33 or 
45) were detected in HPV positive cases. The mean age 
of patients in combined HPV DNA positive group A+B 
was 40.6 years while in HPV DNA negative group C it was 
61.9 years. In the combined A+B group 87.5 % of patients 
showed anamnestical data of high-grade VIN, usual type. 
No such diagnosis was disclosed in the history of patients 
in group C. In the combined group A+B 62.5 % of patients 
and 12.5 % of patients in group C had a history of CIN le-
sions. Fifty percent of patients from combined A+B group 
and none from the group C were immunocompromised 
(2x kidney transplantation, aplastic anaemia and systemic 
lupus erythematosus).
CONCLUSION
The results suggest that the category of mild vulvar sq-
uamous dysplasia may be appropriate to retain in younger 
women, in patients with a history of high-grade VIN, in 
women with a history of CIN as well as in immunosu-
pressed patients. In these cases, lesions of VIN I appear-
ance should be classified and managed as dysplastic. The 
pattern of VIN I in the field of vulvar inflammatory dis-
orders represents more epithelial reactive changes than 
a manifestation of HPV related carcinogenetic pathway. 
Therefore, these lesions should not be classified as VIN 
I, usual type. Their significance in the pathogenesis of 
the VIN, differentiated type (VIN III) in the environment 
of lichen sclerosus – lichen simplex chronicus is to be 
further clarified.
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AIM
To investigate genes involved in pulmonary carcino-
genesis by examining gene expression profiles of non–
small-cell lung cancers to identify molecules that might 
serve as diagnostic markers or targets for development 
of new molecular therapies. A gene encoding ADAM8, 
a disintegrin and metalloproteinase domain-8, was se-
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lected as a candidate for such molecule. Tumor tissue 
microarray was applied to examine expression of ADAM8 
protein in archival lung cancer symplex from 363 patients. 
A patient file of 300 lung cancer patients and 72 controls 
was used.
RESULTS
ADAM8 was abundantly expressed in the great ma-
jority of lung cancers examined. A high level of ADAM8 
expression was significantly more common in advanced 
stage IIIB/IV adenocarcinomas than in adenocarcinomas 
at stages I–IIIA. None of the normal lung tissue including 
preinvasive lesions expressed ADAM 8. The relationship 
between expression of ADAM 8 and clinical parameters 
was being investigated.
DISCUSSION
We found that ADAM8 was abundantly expressed in 
the great majority of lung cancers examined. A high level 
of ADAM8 expression was significantly more common in 
advanced stage IIIB/IV adenocarcinomas than in adeno-
carcinomas at stages I–IIIA. This is to our knowledge the 
first study to investigate the immunohistochemical expres-
sion of ADAM 8 and correlate it to the clinical outcome 
in non small cell lung cancer patients.
Several studies have found that serum levels of 
ADAM8 were significantly higher in lung cancer patients 
than in healthy controls. The proportion of the serum 
ADAM8-positive cases defined by our criteria was 63 % 
and that for carcinoembryonic antigen was 57 %, indi-
cating equivalent diagnostic power of these two markers. 
(2,3,6). Other authors used a combined assay with the 
benefits of both ADAM8 and carcinoembryonic antigen 
increased sensitivity because 80 % of lung cancer patients 
were then diagnosed as positive,whereas only 11 % of 72 
healthy volunteers were falsely diagnosed as positive. In 
addition, exogenous expression of ADAM8 increased the 
migratory activity of mammalian cells, an indication that 
ADAM8 may play a a significant role (1,4,5) in progres-
sion of lung cancer.
CONCLUSIONS
These data suggest that ADAM8 should be useful as a 
diagnostic marker and probably as a therapeutic target.
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During the last 20 years major advances have been 
achieved in our knowledge of cardiomyopathies (CMs), 
particularly the discovery of new CMs, update of the clas-
sification, and the understanding of etiopathogenesis.
Among new entities are arrhythmogenic right ven-
tricular CM, primary restrictive CM, and noncompacted 
myocardium CM. In 1995, the WHO put forward a new 
definition of CM – “disease of the myocardium associated 
with cardiac dysfunction”, replacing the previous “heart 
muscle disease of unknown etiology”. What was consid-
ered for years to be idiopathic has been largely elucidated 
as having a genetic background (e.g. hypertrophic CM), 
or a viral etiology (e.g. dilated CM).
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Key words: Prostate cancer/Screening/Early detection/PSA
OBJECTIVE
The aim of the study KAPROS (carcinoma of the pros-
tate) was to obtain elementary epidemiological urological 
data on the male population aged 50 to 70 years in the 
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Olomouc region with emphasis on prostate cancer, BPH 
and erectile dysfunction. This is an extensive study, also 
the first one of its size ever performed in the field of Urol-
ogy in the Czech Republic.
METHODS
The study was prospective with data collected from 
2852 respondents older than 40 years in the Olomouc 
region in the period June 2004 to September 2005 using 
a questionnaire.
RESULTS
On the basis of PSA elevation, prostate biopsy was 
indicated in 101 men out of 2852 respondents. Prostate 
cancer was subsequently confirmed in 24 samples.
The data showed that PSA level was ≤ 2.5 in 90 % 
men, 2.5-10 in 9 % and > 10 in 1 % only out of 2852 
tested men.
No correlation of family history and PSA level was 
found.
The number of man with PSA level > 2.5 significantly 
increased with age.
Index fPSA/PSA ≤ 20 % was detected in 30.5 % men 
with a PSA level 2.5–10.
It was interesting to discover that there exists a statisti-
cally significant difference in distribution of the PSA level 
in smokers and non-smokers where the PSA level is higher 
in nonsmokers than in smokers.
CONCLUSION
Several interesting facts emerge from these data. The 
average incidence of CaP in the Czech Republic is 72/
100 000. In our study, the male sample was only informed 
using a questionnaire. CaP was detected in 24 men which 
is an of 825/100000. This number may be altered by the 
selection of men (age 50–70 years), yet the number is 
striking.
The relatively low distribution of PSA levels in age 
groups does not exclude the existence of CaP [1]. Chang-
es in PSA-PSA velocity (PSAV)[2] will be surely interest-
ing. The higher rate of non-smokers with the PSA level 
> 2.5 was surprising. The PSA levels in smokers were sta-
tistically proved to be lower. This difference is 0.1 ng/ml 
and should be considered in the diagnosis of the prostate 
cancer.
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BACKGROUND
Perivascular tumours comprise glomus tumour and 
myopericytoma. Tumours showing features intermediate 
between glomus tumour and myopericytoma have been 
designated glomangiopericytomas. Perivascular myoid 
cells can evolve into smooth muscle cells, tumours with 
this type of differentiation are known as perivascular myo-
mas. Perivascular tumours are only rarely described in 
deep soft tissue or viscera.
DESIGN
We demonstrate a case of a 68 year old woman with 
perivascular myoma in the superior mediastinum which 
showed features of glomangioma, myopericytoma and 
angioleiomyoma.
RESULTS
A 68 year old woman was admitted to hospital for 
cough and thoracic pain. CT scan revealed a tumour in 
the superior mediastinum and the patient underwent 
surgery. The tumour was circumscribed and unencapsu-
lated. The cut surface was fibromyxoid. Microscopically, 
the tumour showed a biphasic pattern that consisted of 
vascular areas with prominent branching vessels lined 
by small endothelial cells and myoid areas with fascicles 
of eosinophilic spindle cells. In vascular areas we found 
clusters of epitheloid cells with a peripheral rim of PAS 
positive material as well as elongated cells concentrically 
arranged around vessels. Immunohistochemically, these 
cells were positive for smooth muscle actin but not for 
desmin. Eosinophilic spindle cells in myoid areas showed 
coexpression of both markers. Mitosis and cytologic aty-
pia were not seen.
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CONCLUSION
To our knowledge this is the first case of mediastinal 
perivascular myoma described to date. Perivascular cells 
showed features of glomus cells and myopericytes: For 
this reason we prefer the designation glomangiopericyto-
myoma. Although these tumours can recur, their benign 
behaviour is assumed.
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BACKGROUND
It is generally is accepted that there no higher preva-
lence of renal diseases occurs in psoriatic patients with 
the exception of secondary amyloidosis in psoriatic ar-
thropathy. In contrast it has been suggested that kidney 
diseases in psoriasis vulgaris may be more common than 
thought and this presumes the existence of psoriatic ne-
phropathy.
DESIGN
We report a case of IgA nephropathy in a patient with 
psoriasis vulgaris as a contribution to the ongoing discus-
sion of around the entity, psoriatic nephropathy.
RESULTS
A 62 year old man with a history of psoriasis vulgaris 
without evidence of psoriatic arthropathy was admitted to 
hospital for nephrotic proteinuria 6.74 g/day and moder-
ate decrease in glomerular filtration rate with creatinine 
213umol/l and creatinine clearance 0.95 ml/s. Kidney 
biopsy revealed IgA nephropathy, a type with diffuse me-
sangial proliferation and focal glomerulosclerosis, severe 
interstitial nephritis and arteriolosclerosis (CsaIV). After 
one month of treatment with Prednisone 1 mg/kg/day 
proteinuria decreased to 2.45 g/day and the skin lesion 
almost completely resolved.
CONCLUSION
About 10 cases of IgA nephropathy accompanied pso-
riasis were referred to in the literature. We report another 
interesting case of IgA nephropathy in a psoriatic patient 
as contribution to the discussion about the still hypotheti-
cal concept, psoriatic nephropathy. We recommend care-
ful examination of kidney function and wider application 
of renal biopsy in psoriatic patients.
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INTRODUCTION
Ovarian carcinoma is the sixth most common female 
cancer in the world. This carcinoma carries the highest 
mortality of all gynecological malignancies. The high mor-
tality is due mostly to the fact that the tumour is frequently 
diagnosed late, in advanced stages (III, or even IV). The 
most important prognostic factors in ovarian carcinoma 
are the extent of the tumour (stage), the size of residual 
tumour following operation, the presence vs. absence of 
ascites, the age and the general condition of the patient 
at the time of diagnosis, the histology of the tumour, and 
in the early stages, also the histological differentiation of 
the tumour (grade).
AIM
The aim of this study was to find immunohistochemi-
cally detectable significant prognostic and predictive mark-
ers for invasive ovarian carcinoma. There were three areas 
of research: (1) the expression of hormonal receptors by 
tumour cells; (2) the assessment of cell growth kinetics 
in ovarian carcinoma by examination of proliferation ac-
tivity by means of antibodies Ki-67 and topoisomerase 
IIα, and (3) the assessment of the angiogenic potential 
of ovarian carcinoma by means of immunohistochemical 
detection of vascular endothelial growth factor, and by 
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quantification of microvessel density at sites of the highest 
angiogenic activity (hot spots).
MATERIAL AND METHODS
A retrospective study was carried out of 116 patients 
with histologically proved invasive ovarian carcinoma 
diagnosed at the Fingerland Department of Pathology 
during the period 1996–2003. The available clinical data 
on tumour stage according to the FIGO classification, 
the size of the residual postoperative tumour, and the 
length of survival after operation were summarized. The 
surgical specimens were routinely fixed in 10 % forma-
lin, processed, embedded in paraffin and stained with 
hematoxylin-eosin. The histological type of the tumour 
and its grade were reviewed. The following panel of im-
munohistochemical reactions was applied: estrogen (ER) 
and progesterone (PR) receptors, proliferation antigens 
Ki-67 and topoisomerase IIα., and vascular endothelial 
growth factor (VEGF). The tumor angiogenic capacity 
determined by density of the capillaries was visualized 
by antibodies against von Willebrand factor – FVIII and 
against antigen CD34. An indirect immunohistochemical 
method using avidine–biotine visualisation system LSAB+ 
was used. The positivity of the reactions was evaluated 
by a light microscope. For ER and PR quantification a 
semiquantitative evaluation was used. The expression of 
Ki-67 and topoisomerase IIα was evaluated quantitatively 
in peripheral parts of the tumor. The VEGF was evalu-
ated semiquantitatively. The quantification of capillaries 
comprised two steps: first, foci with the highest density of 
capillaries (“hot spots”) were identified in slides stained 
with antibody against FVIII and CD34, under low magni-
fication. This was followed by quantification of individual 
capillaries within the „hot spots“. For statistics, the high-
est number of capillaries in the tumour and the average 
density of capillaries were considered. For statistical 
evaluation the program NCSS was applied. The time of 
overall survival was evaluated by Kaplan-Meier method, 
the individual factors were compared with log-rank test, 
and Cox method was used for multivariate analysis.
RESULTS
A total of 116 patients, aged 27–55 years (mean age 
55.2 y.) were evaluated. The estrogen receptors were 
positive in 76 carcinomas (65.6 %), the progesterone 
receptors in 52 carcinomas (44.8 %). The proliferation 
antigen Ki-67 was expressed in 6.9 – 98.1 % of the tumour 
cells (median 41.9 %), and the proliferation antigen 
topoisomerase IIα in 4.1 – 92 % of the tumour cells 
(median 35.2 %). VEGF was positive in 80 carcinomas 
(69 %). The mean microvessel density was 27.8 – 213.9 
capillaries per mm2 (median 77.8) when using antigen 
FVIII, and 43 – 379.2 capillaries per mm2 (median 150) 
when using antigen CD34. The maximal microvessel 
density was 33.3 – 229.2 capillaries per mm2 (median 
83.3) when using antigen FVIII, and 45 – 387.5 capillaries 
per mm2 (median 164.6) when using antigen CD34.
In univariate analysis, age (p = 0.02), FIGO stage 
(p = 0.000004), residual tumor (p = 0.0002), grade 
(p = 0.02), Ki-67 (p = 0.005), topoisomerase IIα (p = 
0.04), progesterone receptors (p = 0.0008), CD34 mean 
microvessel density (p = 0.01) and CD34 maximal 
microvessel density (p = 0.05), were all associated with 
survival. In multivariate analysis, the factors that were 
independent predictors of survival were only age (p = 
0.01), residual tumor (p = 0.0004), FIGO stage (p = 0.02) 
and CD34 mean microvessel density (p = 0.004).
CONCLUSION
The presented data suggest that the only immunohis-
tochemically detectable significant prognostic marker for 
invasive ovarian carcinoma is microvessel density by using 
antigen CD34.
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AIM
Invasive ductal and lobular breast carcinomas account 
for 80 % and 15 % of all invasive breast tumors, respec-
tively. Both tumor types are derived from the terminal 
ductal-lobular unit of the mammary gland. However, de-
spite a number of similarities, some clinical follow-up data 
and metastatic patterns suggest that they are biologically 
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distinct and some studies report differences in gene ex-
pression profiling. A major difference exists for example in 
expression of E-cadherin which is almost completely ab-
sent in lobular cancer. A few papers suggest several genes 
are differentially expressed in ductal and lobular tumors. 
The aim of this study was to extend knowledge of differ-
ential gene expression profiles in these carcinomas.
PATIENTS AND METHODS
We examined 10 mastectomy specimens from post-
menopausal breast cancer patients. Of these 5 were inva-
sive ductal, and 5 were lobular carcinomas. Tumor and 
normal tissues were snap-frozen in liquid nitrogen. Frozen 
sections were stained by hematoxylin in RNase-free condi-
tions. Ductal and lobular tumor cells were microdissected 
from cryosections using VeritasTM Laser Capture Micro-
dissection System. Fifty nanograms of total RNA were 
amplified by combined PCR and in vitro transcription. 
Samples were analysed by Affymetrix Human Genome 
U133 Plus 2.0 Arrays. Gene expression analysis was per-
formed by Affymetrix Gene Chip Operating Software, 
dChip software and Internet databases.
RESULTS
Upregulated genes were as follows: ASPN (asporin), 
leucine-rich repeat protein with porin activity; EMP1 
(epithelial membrane protein 1) involved in cell growth 
and proliferation; DVL1 (Dishevelled, dsh homolog 1) 
with signal transducer activity, involved in Wnt signaling 
pathway; ENC1 (ectodermal-neural cortex) participating 
in actin and protein binding; THBS4 (thrombo spondin-4), 
adhesion molecule involved in calcium ion, protein and 
heparin binding; ANGPTL2 (angiopoietin-like 2) involved 
in receptor binding; ACACB (Acetyl-Co enzyme-A car-
boxylase-beta) important in fatty acid synthesis, nucle-
otide, biotin and ATP binding; FOXP1 (Forkhead box 
P1) participating in nucleic acid, zinc and metal ion 
binding, with transcription factor activity. Downregulated 
genes include PPP3CB (protein phosphatase 3), PCSK6 
(proprotein convertase subtilisin), YWHAB (tyrosine 
3-monooxygenase) and DDR1 (discoidin domain recep-
tor family member 1) which are involved in calcium sign-
aling pathway; IRAK1 (interleukin-1 receptor-associated 
kinase 1) possessing NF-kappaB-inducing kinase activity; 
PRKCI (protein kinase C, iota) participating in G protein 
and Wnt signaling pathways; CHML (Rab escort protein 
2) and RHOU (RAS homolog gene family, member U) 
are important in GTP binding; ADNP (activity-depend-
ent neuroprotector) with transcription factor activity 
and NRIP1 (nuclear receptor interacting protein 1) with 
transcription coactivator/corepressor activity, capable of 
nuclear hormone receptor binding. CDH1 (E cadherin) 
was downregulated in all lobular carcinomas.
CONCLUSION
Gene sets, differently expressed in invasive ductal and 
lobular breast carcinomas, are involved in cell growth and 
proliferation, calcium, G-protein and Wnt signaling path-
ways, nucleic acid, nuclear hormone receptor, zinc ion 
binding and transcription factor activity suggesting that 
invasive growth of ductal and lobular tumor cells may be 
mediated by different genetic mechanisms. Some of these 
genes may prove to be important for diagnostic purposes 
and as potential targets for therapy against specific tumor 
types.
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AIM
Transforming growth factor beta1 (TGFbeta1) induces 
growth arrest in many cell types, including B lymphocytes. 
The inhibitory action of TGFbeta1 is mediated by deacti-
vation of cell cycle machinery. Several feedback-sensitive 
pathways determine whether the cells are stopped in G1 
phase or are allowed to leave the G1 phase and enter 
the S phase. The cell-cycle engine is tightly controlled by 
cyclin-dependent kinase (cdk) inhibitors which mediate 
extracellular negative signals, resulting in cell-cycle arrest 
at different G1 points. In this study, we tried to elucidate 
whether cyclin-dependent kinase inhibitors (CKIs) may 
become targets for the inhibitory signalling pathways in-
duced by TGFbeta1.
MATERIAL AND METHOD
Our experimental DoHH2 cell line model was derived 
from a patient with malignant non-Hodgkin’s lymphoma 
of follicular origin. The effect of TGFbeta1 on cell cycle 
progression was studied by flow cytometry. We examined 
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the effect of TGFbeta1 on the expression of p21WAF1 by im-
munoblotting and RT-PCR. The binding activity of tran-
scription factors to promoter of p21 gene was determined 
by gel mobility shift assay (GMSA).
RESULTS
Our results showed that the treatment of TGFbeta1 in-
creased the number of cells which are arrested in the G0/
G1 phase compared to untreated control cells. Moreover, 
we found that expression of p21WAF1 was significantly up-
regulated on the protein level after TGFbeta1 treatment. 
Similar to the protein level, the expression of p21 mRNA 
was increased in TGFbeta1 treated cells. We further exam-
ined binding activity of Sp family of transcription factors 
to examine their role in p21WAF1 up-regulation.
CONCLUSIONS
The results indicate that p21WAF1 overexpression in 
TGFbeta1-arrested malignant B cells is mediated by 
binding of Sp1 and/or Sp3 transcription factors to the (-
92/-71), (-77/-58) and (-65/-45) elements of the promoter 
region of the p21 gene.
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AIM
Would a proper diagnostic approach to an elderly pa-
tient reveal the diagnosis ante mortem?
BACKGROUND
82-year old man with clinical diagnosis of myelodys-
plastic syndrome lasting two years was admitted to the 
hospital dehydratated, febrile, with anaemia, leukopenia, 
thrombocytopenia, hypogammaglobulinemia and upper 
dyspeptic syndrome. The patient died after 3 days of bi-
lateral bronchopneumonia and a consequent sepsis.
MATERIAL AND METHODS
The diagnosis of the myelodysplastic syndrome was 
made by an outpatient-department hematological special-
ist 2 years ago and this diagnosis was based on the clinical 
status and examination of the peripheral blood (hemat-
ocrite, vitamin B12, ferritin). Specifically, trepanobiopsy 
and bone marrow examination was not perfomed. The 
patient was treated with blood transfusions and corticos-
teroids. The autopsy was performed 17 hours after the 
patient’s death. The patient was cachectic, had excentric 
heart hypertrophy with a diffuse myofibrosis, and bilateral 
bronchopneumonia. Hepatosplenomegaly (liver 2200 g, 
spleen 600 g) and moderate enlargement of the kidneys 
(350 g) were the most conspicuous gross findings. Micro-
scopical examination of formalin-fixed, paraffin-embedded 
tissue from the bone marrow (vertebral body and femoral 
bone marrow), liver, spleen and kidneys stained by hema-
toxylin-eosin revealed excessive numbers of macrophag-
es phagocytosing a crystalic material. Various staining 
methods including PAS, AB-PAS, Giemsa, Gram, Mas-
son’s trichrom and mucicarmine, immunohistochemical 
(light immunoglobulin chains kappa and lambda, CD68, 
MUM1, CD138) and electronmicroscopical examinations 
were utilized to identify the origin of the crystals. The 
bone marrow was also examined using Gömöri silver im-
pregnation.
RESULTS
The bone marrow was hypocellular, trilinear without 
dysplastic changes and without fibrosis. The crystals were 
found phagocytosed in macrophages, and also extracel-
lularly inside the renal tubules. The crystals were of a 
proteinaceous origin, had a shape of hexagonal bipris-
mas. They revealed no autofluorescence and the polarized 
light showed no signs of birefringence. The crystals were 
positive in all stainings except for mucicarmine. The im-
munohistochemical examination of bone marrow revealed 
a disperse population of monoclonal plasma cells with a 
kappa light chain restriction. Their amount was estimated 
to form, at least focally more than 15 % of cells of the 
bone marrow.
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CONCLUSION
The autopsy findings, together with extensive micro-
scopical and immunohistochemical examinations identi-
fied the proper cause of the disease and contributed to an 
appropriate diagnosis: plasmocytoma secerning parapro-
tein and causing a generalized crystal storage histiocytosis. 
In case, if the patient had had the bone marrow investiga-
tion and appropriate biochemistry tests performed at the 
beginning of his initial symptoms, this would have led to 
a proper diagnosis and treatment.
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OBJECTIVE
The growth in incidence of prostate carcinoma is evi-
dent as the population grows older.
If the CaP is detected in time, there are various treat-
ment strategies. One curative treatment possibilities is 
retropubic radical prostatectomy (RRP). Apart from the 
clinical stage, histopathological grading (Gleason score) 
plays a crucial role in the indication for this surgical treat-
ment and potential subsequent therapy (hormonal/radio-
therapy).
The aim of this study was to evaluate the correlation 
of Gleason score from the biopsy of the prostate and the 
specimen after retropubical radical prostatectomy (RRP) 
in patients with carcinoma of the prostate.
METHODS
We retrospectively reviewed the records of 364 pa-
tients (age 35–74 years) who underwent RRP for prostate 
cancer from 1997 to 2004: 339 patients were evaluated. 
Gleason score data were collected from the prostate bi-
opsy and subsequent retropubical radical prostatectomy 
specimen.
RESULTS
Correlation GS from biopsy and RRP specimen 
(n = 339)
GS – biopsy correlation higher lower
2–6 
(n =273) 47 (17,2 %) 206 (75.5 %) 20 (7.3 %)
7–10 
(n = 66) 31 (47 %) 20 (30 %) 15 (21 %)
Total 
(n = 339) 78 (23 %) 226 (66.7 %) 35 (10.3 %)
CONCLUSION
Correlation of the GS is only 23 % which raises the 
question whether the pre-operative Gleason score is a reli-
able predictive factor. Only the Gleason score made on a 
specimen after RRP allows us to prediction the possible 
future tumor progression. The outcomes of the non-surgi-
cal methods of treatment (radiotherapy, brachytherapy, 
HIFU) are also probably influenced by the low correla-
tion.
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AIM
Mismatch repair gene defects are the mainstay of the 
hereditary non-polyposis colorectal cancer syndrome. 
However, they are also present in aproximately 10–15 % 
sporadic cancers. The literature on these findings in spo-
radic adenoma of the large bowel is scarce.
PATIENTS AND METHODS
We analysed 118 sporadic colorectal adenomas from 
118 patients. Basic histology was followed by an immu-
nohistochemical analysis of both main proteins of MMR 
system: MLH1 and MSH2. The immunohistochemistry 
results were compared with the following parameters of 
adenomas: malignant potential (assessed by the size of 
adenoma, histology and grade of dysplasia), location of 
adenoma in the bowel, type of growth, and age of patient. 
We also compared the results with those obtained in a 
small group of patients with colorectal carcinoma.
RESULTS
Immunohistochemical examination revealed loss of 
MLH1 protein in 11 adenomas (9.3 %) and loss of MSH2 
in 6 adenomas (5.1 %). We observed two cases of synchro-
nous absence of both MLH1 and MSH2. Therefore, the 
total number of adenomas without MLH1 and/or MSH2 
was 15 (12.7 %). In 15 cases of patients with colorectal 
cancer, loss of MMR proteins was found in two cases 
(13.3 %). When we compared the results of immunohisto-
chemistry with the characteristic of adenomas, we found 
no correlation between expression of MMR proteins and 
grade of malignant potential, location of adenoma in the 
bowel, type of growth, or age of patient. The results of 
immunohistochemistry were comparable with analysis of 
microsatellite instability in a small subgroup of patients 
analysed for this parameter.
CONCLUSION
We found no relationship between MLH1 and MSH2 
expression in colorectal adenomas and their malignant 
potential, location in the bowel, type of growth, and age 
of patient. In this regard, adenomas differ from findings 
described for colorectal carcinomas.
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AIM
Lymphocytic infiltrate in muscle of patients with 
myasthenia gravis (MG) and thymoma was reported re-
peatedly as a coincidental autoimmune polymyositis. In 
this study we aim at providing evidence that most cases 
of such a “polymyositis” do not represent a myositis per 
se, but only a paraneoplastic event.
MATERIAL AND METHODS
An excision from the sternothyreoid muscle taken 
during thymectomy was examined histopathologically in 
28 patients with diagnosed MG and thymoma. Provided 
that lymphocytic infiltrates were found, we performed 
immunohistochemistry to establish their immunophe-
notype (CD20, CD3, CD4, CD8, TdT, CD68). Further, 
an antibody against CD45RA antigen (physiologically 
present in B-cells and mature but naive T-lymphocytes) 
was applied. We also searched immunohistochemically 
for the expression of HLA-ABC antigens on the surface 
of the muscle fibers. The immunophenotype of thymoma-
lymphocytes was also analyzed. The findings in muscles 
were compared with those obtained in 14 patients with 
definite polymyositis.
RESULTS
In all polymyositis cases, the inflammatory infiltrate was 
composed mostly of CD8+CD4- T-lymphocytes and scat-
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tered macrophages and there was a strong diffuse expres-
sion of HLA-ABC antigens found on the surface of muscle 
fibers. All the CD8+ cells were CD45RA negative.
In 16 patients with MG and thymoma the lymphocytic 
infiltrates were identified in muscles and they were mor-
phologically indistinguishable from those in polymyositis. 
However, the expression of HLA-ABC was limited to the 
muscle fibers close to the lymphocytic infiltrates, all other 
fibers were negative. The lymphocytes were CD8 positive, 
but a small proportion of them co-expressed the CD4 
antigen. The CD8+ T-lymphocytes were simultaneously 
CD45RA positive. The thymic tumors of the 16 patients 
were all thymomas of type B or AB. No lymphocytes were 
found in muscles in MG patients with type A thymoma. 
Although most of the intratumoral lymphocytes were 
TdT+ immature T-cells, we have identified a proportion 
of CD8+CD45RA+ cells admixed to the thymocyte-popu-
lation. Clinically, the MG patients with the lymphocytic 
infiltrates in muscle did not differ significantly (both in 
the preoperative presentation and in the follow-up analy-
sis) from those without the infiltrates. In both groups, the 
muscle weakness improved after the thymoma removal.
CONCLUSION
It has been shown previously that the proportion of 
CD8+CD45RA+ lymphocytes is significantly increased 
in the blood of patients with thymomas (Hoffacker et al., 
2000). We identified CD8+CD45RA+ T-cells in cortical 
thymomas and demonstrated that the cells of the polymy-
ositis-like lymphocytic infiltrates in muscles have the same 
immunophenotype, different from that of polymyositis. 
Therefore, we suggest that the lymphocytic infiltrates in 
patients with MG and thymoma represent more likely a 
paraneoplastic event due to the “spillover” of thymoma-
derived mature naive T-cells than a real cell-mediated 
autoimmune disorder. The finding CD8+ CD45RA+ lym-
phocytes in muscle biopsies (especially in MG patients) 
should not be interpreted as a polymyositis, but should 
lead to the exclusion of an underlying thymic neoplasm.
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AIM
To evaluate the frequency and histological types of 
lymphomas of the small intestine in the biopsy register 
at the Institute of Pathology in Brno over the last five 
years.
MATERIAL AND METHODS
A retrospective study was performed on 9 surgical pa-
thology cases of the small intestine. In seven cases there 
were lymphomas of the jejunum, in one case the terminal 
ileum was infiltrated and in one case the lymphoma in-
filtrated the ileocoecal region. Tumors were examined by 
light microscopy, immunohistochemistry and the FISH 
method. The patients were admitted mostly with recent 
abdominal symptomatology, intestinal obstruction or per-
foration.
RESULTS
DLBCL (difuse large B-Cell lymphoma) predominated 
in the series and had the same histological pattern as lym-
phomas of the lymph nodes. Bcl-2 was positive in a range 
from < 1 % to 80 % of cells. Bcl-6 was positive (> 10 % of 
tumor cells) in 3 of 5 cases.
In 2 cases of follicular lymphoma, infiltration of sur-
rounding lymph nodes and soft tissues around the intestine 
were found. Histologically, with follicular arrangement of 
the tumor cells, grade 1. Immunohistochemistry showed 
CD20, CD79a, CD10, Bcl-2 positivity; CD5, CD45RO 
negativity. FISH method for translocation t(14;18) was 
positive in more than 90 % of cells in both cases. One 
case had MCL (mantle cell lymphoma) morphology in 
duodenal region. The lymphoma cells were immunoreac-
tive for CD20, CD79a, CD5, cyclin D1 and negative for 
CD20, CD23, CD10. One case of ALCL (anaplastic large 
cell lymphoma) was diagnosed with the immunoprofile: 
CD3, CD45RO, CD43, CD30 positivity; CD20, CD79a, 
CD23, CD10 negativity. More than 90 % of tumor cells 
were Ki-67 positive.
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CONCLUSIONS
Nine primary lymphomas of the small intestive were 
examined by light microscopy, immunohistochemistry 
and FISH method. The most frequent lymphoma type was 
DLBCL. Lymphomas were Bcl-6 positive in 3 cases and 
all CD10 negative. They are probably derived from ger-
minal and non-germinal center B-cells. Rarely, 2 follicular 
lyphomas penetrated to the lymph nodes and soft tissues 
around the intestinum. According to literature prognosis 
is better than for lymph node localization. In our cases 
the clinical follow-up was only several months.
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In a group of 30 laryngeal resections with invasive spinocellular carcinoma the authors studied the unchanged 
mucous structures in the supraglottic, glottic and subglottic areas. Mucosal samples were taken and their examination 
was focused on standard dysplastic changes using basic colouring hematoxylin-eosine and other special methods. Im-
munohistochemical examination (p53, Ki 67, p16) showed positivity only in advanced stage dysplasia and in carcinoma 
in situ. Chronic inflammatory changes were commonly found. The authors suggest that viral aetiology should not be 
underestimated along with other risk factors.
INTRODUCTION
Human papillomaviruses (HPV) are associated with 
a range of epithelial localisations, especially in the areas 
of the cervix uteri, skin, oropharynx and larynx. Laryn-
geal tumours are among the most common ones in ENT. 
Condyloma formations and condyloma-like lesions can 
be found, as well as squamous papilloma, focal epithelial 
hyperplasia, dysplastic and neoplastic changes. In the 
laryngeal area, neoplasia occurs most commonly in the 
supraglottic and glottal areas and subglottal localisation 
was found to be very rare7. Laryngeal carcinoma accounts 
for 1 % of all tumours and 0.73 % of all lethal malignant 
diseases are due to laryngeal carcinoma13. The average 
annual incidence of laryngeal carcinoma in the Czech 
Republic is 5.09 cases per 100,000 of the total popula-
tion. The ethiopathogenesis of the laryngeal cacinoma 
is multifactorial with multicentric occurence and „field 
cancerization“15.
MATERIALS AND METHODS
The selected study group (cohort) consisted of 30 indi-
viduals with laryngeal carcinoma – 29 men and 1 woman 
aged 54. The age of the men ranged from 41 to 80 years 
with an average age 57.3 years. The majority of the se-
lected individuals were smokers who occasionally used 
alcoholic beverages.
Samples from the 30 laryngeal resections were exam-
ined histopathologically and were described both macro-
scopically and microscopically following fixation in 10% 
formalin (Pictures 1, 2). The tissues were processed by 
the paraffin method and other special methods (PAS, Go-
mori, VG) and immunohistochemical methods focused on 
showing changes suggestive of tumor proliferation (p52, 
Ki67, p16) (Pictures 3–5).
Following the diagnosis of a tumor lesion (in all these 
cases this was spinocellular carcinoma with invasion of 
varying degrees of differentiation), histopathological ex-
amination focused on macroscopically intact mucosal 
parts with standard samples taken from the supraglottis, 
glottis and subglottis. The distance of the site where sam-
ples were taken from to the localisation of carcinoma was 
at least 10 mm. Cases not complying with this criterion 
were excluded.
Mucosal samples from macroscopically nontumor-
ous sites were examined in detail with the focus being on 
epithelial changes as hyperplasia, metaplasia and dyspla-
sia, and examined using basic, special and immunohisto-
chemical methods.
RESULTS
The histopathological findings in individual laryngeal 
areas are shown in Table 1. Assessment of the histopatho-
logical examinations was focused on chronic inflamma-
tory changes, the occurence of acanthosis, parakeratosis, 
hyperplasia and squamous-cell metaplasia. The frequency 
of the aforementioned changes shows the prevalence of 
chronic inflammation in the glottal area while chronic 
inflammatory changes in the supraglottal area were found 
to be significantly lower. Other changes – acanthosis, par-
akeratosis and epithelial hyperplasia were more common 
in the supraglottal area. Squamous-cell metaplasia was 
assessed only in those places where it replaced normal 
respiratory epithelium. The occurrence of squamous-cell 
metaplasia in glottal and subglottal areas was 15.6 %.
Dysplasias were found 56 % of all samples in supra-
glottal areas while in glottal areas only 15.2 %. This differ-
ence was highly statistically significant (Table 2). It was 
not possible to statistically assess the other comparisons 
due to the presence of zero occurences in one area.
63
Table 1. The frequency of finding specifications in individual sites.
Finding specification
Supraglottis Glottis Subglottis
N % N % N %
Normal finding 0 0.0 1 3.0 3 9.3
Chronic inflammatory changes 2 5.8 20 60.6 24 75.0
Acanthosis 2 5.8 0 0.0 0 0.0
Parakeratosis 3 8.8 1 3.0 0 0.0
Hyperplasia 6 17.6 0 0.0 0 0.0
Squamocellular metaplasia 0 0.0 6 18.2 5 15.6
Dysplasia total 19 55.9 5 15.2 0 0.0
light 15 44.3 3 9.1 0 0.0
medium 2  5.9 2 6.1 0 0.0
heavy 2  5.9 0 0.0 0 0.0
Carcinoma in situ 2 5.9 0 0.0 0 0.0
Number of findings total 34 100.0 33 100.0 32 100.0
Table 2. The results of statistical comparison of dysplasia findings in individual sites.
Comparison of dysplasia findings in individual sites
Supraglottis: glottis Glottis: subglottis Supraglottis: subglottis
X2(1) = 15.322 P = 0.0000 Not possible to evaluate Not possible to evaluate
Fig. 1.  Laryngeal resection – supraglottic form of carci-
noma
Fig. 2. Laryngeal resection – glottic form of carcinoma
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Fig. 3. Laryngeal mucosa, medium dysplasia, p16, 200x Fig. 4. Laryngeal mucosa, heavy dysplasia, p53, 200x
Fig. 5. Laryngeal mucosa, carcinoma in situ, p53, 200x
Immunohistochemical examinations (p53, Ki67, p16) 
were applied to tissue samples with histologically proved 
dysplastic changes using hematoxylin- eosine. Immuno-
histochemical examination in dysplastic lesions including 
carcinoma in situ (CIS) revealed positivity in 10 cases: us-
ing applied antibodies, p53 positivity was found in 5 cases, 
Ki67 positivity in 3 cases and p16 positivity in 2 cases. 
Chronic inflammatory changes were common in the total 
laryngeal areas studied and round cell cellulisation with 
pevailing presence of plasmocytes was noted. Squamous 
cell epithelium showed, especially in supraglottal parts 
with hyperplastic changes in basal layers, and parakera-
tosis and acanthosis in 5 cases. Koilocytar changes were 
found in one case. Squamous-cell metaplasia replacing 
normal respiratory epithelium was found in 11 cases of 
larynxes examined.
DISCUSSION
Analysis of the histopathological findings follows from 
previous studies which assess histopathological findings in 
laryngeal carcinoma and mucosal changes4, 5. Amongst fac-
tors that play an important role in dysplastic and neoplas-
tic changes of the larynx, HPV infection is to be ranked 
alongside those of age, mouth hygiene, cancerogenic sub-
stances, tobacco and alcoholic beverage consumption2. 
Studies assessing dysplastic laryngeal changes published 
in the literature are well-known and distinct using hema-
toxylin-eosine12. With further study of these lesions, im-
munohistochemical examination has been increasingly 
used in both tumorous and nontumorous lesion analysis. 
It is important to detect HPV DNA in papillomatous 
carcinoma structures, where HPV 11 is confirmed14. Im-
munohistochemical changes show frequent positivity of 
p53 and p16 detection16. By using Ki67 and p53 in the 
diagnosis of adenosquamous carcinoma, squamous and 
glandular components can be differentiated1. Using p53 
expression, a prognosis of squamous cell carcinoma can 
be made from examination of the oral region8. Tumor-
ous changes of the laryngeal mucosa are studied using of 
molecular genetics that have shown loss of heterozygote 
status and thus the period of survival can be more pre-
cisely determined. Accumulation of p53 is in accordance 
with survivin expression an apoptosis inhibitor in laryn-
geal squamous carcinomas. Expression lies in protein 
inhibition11. Stromal fibromyoblasts positive in SMA and 
CD34 are suggested for differentiation of stromal mucosa 
changes in atypical hyperplasia and squamous laryngeal 
carcinoma13. Maspin, a tumor suppressor gene correlates 
with p53. It plays an important role in laryngeal carci-
noma especially in making a prognosis. Cytoplasmatic 
expression of maspin is found in 47 % of cases. Nuclear 
localisation of maspin is a good prognostic factor in the 
diagnosis of spinocellular carcinoma9.
Our findings revealed using hematoxylin-eosine dye, 
the histopathological changes with dysplasia that have 
taken place and we were able to determine the degree of 
disease progression. The benefit of immunohistochemical 
methods has been proved only for dysplastic lesions of a 
higher degree (in advanced dysplasia and CIS). Dysplas-
tic changes are more common in the supraglottal areas, 
koicylocytar changes were found in supraglottal area in 
one case only.
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Chronic inflammatory changes prevail especially in 
glottal and subglottal areas. These histopathological find-
ings corresponding to acanthosis and parakeratosis do 
not exclude a viral aetiology. These findings were present 
especially in the supraglottal areas. Squamous cell meta-
plasia was found most commonly in the glottal areas. In 
association with these findings other aetiologic agents 
presenting as risk factors in the larynx can be taken into 
account, especially smoking, the mutagenic effects of to-
bacco, especially the smoke from cigerettes and the drink-
ing of alcoholic beverages, which are also suggested by 
the results of our study. The effect of spirits (drinks with 
higher alcohol content) is obvious especially in supraglot-
tic carcinoma3.
Based on the results it is possible to predict that can-
cerogenesis of the epithelium in the supraglottic areas can 
be greatly influenced by risk factors that dominate over 
and above the viral aetiology.
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We examined 40 cases of multiple myeloma (MM) treated with high-dose chemotherapy and autologous transplan-
tation of hematopoetic stem cells. We focused on comparing micro vessel density of bone marrow tumor infiltration 
at preliminary trepanobiopsy and after treatment in a 4–6 month time interval. The blood vessel sections (2–3 μm 
thick) were labeled with anti CD34 (DAKO, clone QBEnd 10) antibody, counted using a calibrated counter at 400x 
magnification on a 0,141 mm2 surface area for each sample, using three different locations which at general magni-
fication showed greatest micro vessel density (hot spots). The average vessel number was then correlated to 1 mm2 
surface area. The SPSS, v. 10.1 (SPSS Inc., Chicago, USA) software was then used for statistical analysis. The results 
were compared using a two-sample t-test at the 0.05 confidence level. A significant decrease in vessel number follow-
ing therapy was discovered during the control trepanobiopsy compared to the preliminary examination in patients in 
remission and with residual disease, regardless of MM differentiation level. In contrast, patients with disease progres-
sion and relapse following a transitory remission showed a significant increase in angiogenesis. Decreased micro vessel 
density is believed to be due to the chemotherapeutic reduction of the tumor infiltration.
INTRODUCTION
Angiogenesis in the stroma of solid tumors has long 
been a topic of interest. It plays an important role in the 
development, progression and dissemination of malignant 
tumors. Within the group of hematological malignities, 
the issue of angiogenesis is extensively studied in multiple 
myeloma (MM), especially in relation to disease progress
ion4, 8, 10, 11, 14, 17, 19. We ourselves compared the micro vessel 
density in MM depending on its morphological differen-
tiation level and bone marrow infiltration type15.
It is assumed that the induction of angiogenesis from 
a pre-existing vascular network depends on the balance 
between a number of angiogenic activators and inhibitors 
in the microenvironment of the tumor. To date, more than 
20 endogenous angiogenesis promoters are known, and 
only a few less factors with an inhibitory effect. These are 
produced by tumor cells, as well as by stromal and inflam-
matory elements2, 5, 7, 18.
It seems that in MM, VEGF (vascular endothelial 
growth factor), which is secreted by myeloma cells, plays 
a key role3, 5, 6, 9, 12. All isoforms of VEGF have tyrosine 
kinase VEGFR (vascular endothelial growth factor re-
ceptor) 1, 2, 3 receptors which are expressed on the en-
dothelial surface of blood and lymphatic vessels as well as 
hematopoetic progenitor cells. It is likely that angiogen-
esis is the result of interaction between malignant cells 
and endothelium by means of paracrine production of 
angiogenic factors. In our work, we focused on evaluat-
ing the effect of high-dose chemotherapy and autologous 
transplantation of hematopoetic stem cells on micro ves-
sel density in MM.
MATERIALS AND METHOD
We studied a set of 40 patients with newly diagnosed 
MM. After high-dose chemotherapy and autologous trans-
plantation of hematopoetic cells, a control biopsy was 
performed within 4 to 60 months after transplantation. 
The patients were divided into 4 groups based on their 
reaction to therapy: remission, residual disease, without 
morphological response, disease progression. As well, 
4 patients who relapsed after a transitory remission were 
evaluated.
All trepanobiopsy samples taken from the hipbone 
were fixated in 10% formalin, decalcified with 10 % chela-
tone and embedded in paraffin. Sections of 2–3 μm were 
stained with HE and a series of special stains (Giemsa, 
PAS, Fe, Gomory, naphthol ASD chloroacetate esterase). 
Immunohistochemical analysis was performed using the 
monoclonal antibodies CD138 (DAKO, clone MI-15), 
light chains of Ig kappa (IMMUNOTECH, clone KP-53) 
and lambda (IMMUNOTECH, clone HP-6054) for deter-
mination of the type, quantity and clonality of the myelo-
ma cell infiltration. The capillaries were labeled with anti 
CD34 antibody (DAKO, clone QBEnd 10). The DAKO 
Cytomation En Vision + system labeled Polymer – HRP 
set was used for visualization.
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Table 1: Remissio
AGE (y.) Timsince month
Vessels. / mm2
biops
Vessels. / mm2
remissio
G N 9 9 9 9
 Minimum 49 9 45.0 26.0
 Maximum 62 33 111.2 42.6
 Median 56.00 11.00 61.50 35.50
 Mean 55.67 16.22 74.14 34.71
 Std. deviation 4.56 9.40 26.12 5.42
G N 3 3 3 3
 Minimum 34 9 59.2 33.1
 Maximum 64 16 78.1 47.3
 Median 62.00 12.00 71.00 37.90
 Mean 53.33 12.33 69.43 39.43
 Std. deviation 16.77 3.51 9.55 7.22
G1 + G N 12 12 12 12
 Minimum 34 9 45.0 26.0
 Maximum 64 33 111.2 47.3
 Median 56.00 11.50 66.25 35.50
 Mean 55.08 15.25 72.97 35.89
 Std. deviation 8.21 8.35 22.74 5.95
Table 2: Residual Disease
AGE (y.) Time since trans months
Vessels / mm2 
prelim biopsy
Yessels / mm2 –
resid. Dis.
G1 N 7 7 7 7
 Minimum 4 6 59.2 42.6
 Maximum 6 4 99.4 56.8
 Median 55.00 11.00 75.70 47.30
 Mean 55.29 14.29 76.09 48.67
 Std. deviation 6.05 11.94 13.68 5.08
G2 N 3 3 3 3
 Minimum 4 6 85.2 42.6
 Maximum 5 3 146.7 56.8
 Median 52.00 8.00 104.10 54.40
 Mean 52.33 16.67 112.00 51.27
 Std. deviation 6.51 16.77 31.50 7.60
G3 N 5 5 5 5
 Minimum 4 8 106.5 33.1
 Maximum 6 3 149.1 142.0
 Median 56.00 9.00 127.80 63.90
 Mean 54.60 13.80 128.26 71.46
 Std. deviation 8.02 11.86 19.62 43.38
G1+G2  N 1 1 1 1
+G3 Minimum 4 6 59.2 33.1
 Maximum 6 4 149.1 142.0
 Median 55.00 9.00 99.40 47.30
 Mean 54.47 14.60 100.66 56.79
 Std. deviation 6.44 11.95 30.55 25.95
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Tab. 3: Without Morphological Reaction to Therapy
AGE Timesince trans
Vessels /mm2
prelim
Vessels / mm2
post th.
G N 5 months 5 biopsy 5 5
 Minimum 45 4 80.5 71.0
 Maximum 65 28 101.8 106.5
 Median 52.00 9.00 92.30 82.80
 Mean 54.60 14.20 92.32 87.56
 Std. deviation 8.20 11.01 9.62 14.09
G N 3 3 3 3
 Minimum 51 6 89.9 56.8
 Maximum 65 60 106.5 120.7
 Median 55.00 27.00 99.40 77.30
 Mean 57.00 31.00 98.60 84.93
 Std. deviation 7.21 27.22 8.33 32.63
G N 1 1 1 1
 Minimum 56 35 146.7 142.0
G1 + G2 + G  N 9 9 9 9
 Minimum 45 4 80.5 56.8
 Maximum 65 60 146.7 142.0
 Median 55.00 24.00 99.40 82.80
 Mean 55.56 22.11 100.46 92.73
 Std. deviation 6.93 18.31 19.33 26.62
Tab. 4: Disease Progression
AG Timesince month
Vessels / mm2
biops
Vessels / mm2
post th.
G  N 4 4 4 4
 Minimum 56 12 42.6 99.4
 Maximum 64 24 63.9 108.9
 Median 61.00 20.50 50.90 102.95
 Meann 60.50 19.25 52.08 103.55
 Std. deviation 3.42 5.25 8.86 4.89
Capillary density was evaluated using the calibrated 
counter at 400x magnification over a 0.141 mm2 surface 
area. Each sample was evaluated this way in three different 
locations, which under general magnification displayed 
the greatest micro vessel density (so-called hot spots). 
The average vessel number was then correlated to a 1 mm2 
surface area. Histological grading of the myeloma cells 
was performed according to criteria set by Bartlem et al.1 
for G1, G2, G3. The prevailing myeloma cell infiltrated 
marrow type was then evaluated. 2 basic infiltration types 
were seen in the patients studied: interstitial and nodular. 
Interstitial infiltration was commonly seen as part of the 
nodular infiltrations. However, it was deemed insignifi-
cant when evaluating micro vessel density because vas-
cularization here was always significantly lower than in 
the nodular zones.
SPSS, v. 10.1 (SPSS Inc., Chicago, USA) software 
was used for statistical analysis. Angiogenesis at prelimi-
nary biopsy and at control biopsy after treatment were 
compared using a two-sample t-test at a 0.05 significance 
level.
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RESULTS
Results are summarized in tables 1–4.
1. Remission at the time of control biopsy was present 
in 12 patients (9 – G1, 3 – G2). The average vessel 
number at preliminary biopsy was 73/mm2, at con-
trol 36/mm2. This difference is statistically significant 
(0.0002).
2. In all 15 cases of residual disease (7 – G1, 3 – G2, 5 – 
G3), a significantly lower vessel number was observed 
in comparison to preliminary examination (0,0001). 
The average vessel number at preliminary biopsy was 
101/mm2, at control 57/mm2.
3. In the group of 9 patients (5 – G1, 3 – G2, 1 – G3), 
where no morphological change in the quantity and 
type of infiltration was observed after therapy applica-
tion, the two-sample t-test did not show a statistically 
significant difference in vessel number (0.325). The 
average vessel number at preliminary biopsy was 100/
mm2, at control 93/mm2.
4. A morphological progression of the disease was ob-
served in 4 patients. These were mostly G1 MM cases, 
where at preliminary biopsy interstitial infiltration was 
present and after therapy nodular infiltrations were 
observed. The average vessel number at preliminary 
examination was 52/mm2, at post-therapy control 
103/mm2. The difference is statistically significant 
(0.004).
5. Disease relapse after transitory remission was observed 
in 4 patients with G1 MM. In remission, the average 
vessel number was 36/mm2, in relapse 73/mm2. This 
difference is also statistically significant (0.010).
It can therefore be stated that the micro vessel density 
in bone marrow infiltrations proportionally increases or 
decreases in direct correlation to morphological changes 
in the infiltrations induced by chemotherapy. Morphologi-
cal remission and residual disease with quantitative infil-
tration decrease was characterized by a significantly lower 
micro vessel density; contrarily, disease progression and 
relapse led to a significant increase in vascularization.
DISCUSSION
The effort to refine the prediction and prognosis of 
patients with malignant tumors leads to searching for new 
factors, which may bring new knowledge in this sense. In 
the last years, considerable attention is focused on angio-
genesis, not only in solid tumors, but also in hematologi-
cal malignancies. It seems that similarly to solid tumors, 
hematooncological diseases exhibit more pronounced 
neovascularization in morphologically less differentiated 
and thus biologically more aggressive tumors8, 10, 11, 13, 14, 19.
When we evaluated micro vessel density in MM in 
our previous work15, we observed that neovascularization 
is greater in less differentiated forms of MM, which are 
usually manifested by the nodular type of infiltration. In 
well-differentiated MM with interstitial infiltration, the 
vessel density is much lower. Evaluating micro vessel den-
sity is therefore, along with the differentiation level of 
myeloma cells and infiltration type, another morphologi-
cal prognostic marker.
This observation is also in accordance with the results 
of our study, which focused on evaluating the reaction of 
high-dose chemotherapy and autologous transplantation 
of hematopoetic stem cells on micro vessel density. It is al-
most surprising how unambiguously it may be stated that 
in patients where therapy induced remission, or at least 
decreased the quantity of infiltration, there was a signifi-
cant decrease in micro vessel density. Contrarily, disease 
progression and relapse always led to a significant increase 
in vessel number. The question remains whether chemo-
therapy acts directly on vascular endothelium, or whether 
the effect is mediated by a reduction in tumor infiltration 
with decreased paracrine production of angiogenic fac-
tors. We can state that the degree of angiogenesis may 
also be of potential therapeutic value. Thalidomide and a 
number of other newly developed substances, which are 
currently being evaluated in relation to therapeutic benefit 
in namely refractory or relapsing forms of myeloma, are 
characterized by their antiangiogenic effect. Evaluating 
angiogenesis in trepanobiopsy may contribute to the de-
termination of patients suitable for antiangiogenic therapy 
in the future.
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